

CF

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
30 March 2006 (30.03.2006)

PCT

(10) International Publication Number
WO 2006/032519 A1(51) International Patent Classification:
A61K 31/4188 (2006.01) C07D 487/04 (2006.01)
A61K 31/4745 (2006.01) A61P 35/00 (2006.01)(74) Agent: SCHREINER, Siegfried; Roche Diagnostics
GmbH, Patent Department (TR-E), Postfach 11 52, 82372
Penzberg (DE).(21) International Application Number:
PCT/EP2005/010312(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY,
MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.(22) International Filing Date:
23 September 2005 (23.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04022753.0 24 September 2004 (24.09.2004) EP
05010528.7 13 May 2005 (13.05.2005) EP(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (for all designated States except US): F. HOFF-
MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse
124, CH-4070 Basel (CH).

Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS

(57) Abstract: Objects of the present invention are the compounds of
Formula (I) their pharmaceutically acceptable salts, enantiomeric forms,
diastereoisomers and racemates, the preparation of the above-mentioned
compounds, medicaments containing them and their manufacture, as
well as the use of the above-mentioned compounds in the control or
prevention of illnesses such as cancer.

WO 2006/032519 A1

Tricycles, their manufacture and use as pharmaceutical agents

The present invention relates to novel tricycles, to a process for their manufacture, pharmaceutical compositions containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents.

5 Protein kinases regulate many different signaling processes by adding phosphate groups to proteins (Hunter, T., Cell 50 (1987) 823-829); particularly serine/threonine kinases phosphorylate proteins on the alcohol moiety of serine or threonine residues. The serine/threonine kinase family includes members that control cell growth, migration, differentiation, gene expression, muscle contraction, 10 glucose metabolism, cellular protein synthesis, and regulation of the cell cycle.

15 The Aurora kinases are a family of serine/threonine kinases that are believed to play a key role in the protein phosphorylation events that are essential for the completion of essential mitotic events. The Aurora kinase family is made up of three key members: Aurora A, B and C (also known as Aurora-2, Aurora-1 and Aurora-3 respectively). Aurora-1 and Aurora-2 are described in US 6,207,401 of Sugen and in related patents and patent applications, e.g. EP 0 868 519 and EP 1 051 500.

20 For Aurora A there is increasing evidence that it is a novel proto-oncogene. Aurora A gene is amplified and transcript/protein is highly expressed in a majority of human tumor cell lines and primary colorectal, breast and other tumors. It has been shown that Aurora A overexpression leads to genetic instability shown by amplified centrosomes and significant increase in aneuploidy and transforms Rat1 fibroblasts and mouse NIH3T3 cells in vitro. Aurora A-transformed NIH3T3 cells grow as tumors in nude mice (Bischoff, J.R., and Plowman, G.D., Trends Cell Biol. 25 9 (1999) 454-459; Giet, R., and Prigent, C., J. Cell Sci. 112 (1999) 3591-3601; Nigg, E.A., Nat. Rev. Mol. Cell Biol. 2 (2001) 21-32; Adams, R.R., et al., Trends Cell Biol. 11 (2001) 49-54). Moreover, amplification of Aurora A is associated with aneuploidy and aggressive clinical behavior (Sen, S., et al., J. Natl. Cancer Inst. 94 (2002) 1320-1329) and amplification of its locus correlates with poor prognosis for 30 patients with node-negative breast cancer (Isola, J.J., et al., Am. J. Pathology 147 (1995) 905-911). For these reasons it is proposed that Aurora A overexpression

- 2 -

contributes to cancer phenotype by being involved in chromosome segregation and mitotic checkpoint control.


5 Human tumor cell lines depleted of Aurora **A** transcripts arrest in mitosis. Accordingly, the specific inhibition of Aurora kinase by selective inhibitors is recognized to stop uncontrolled proliferation, re-establish mitotic checkpoint control and lead to apoptosis of tumor cells. In a xenograft model, an Aurora inhibitor therefore slows tumor growth and induces regression (Harrington, E.A., et al., Nat. Med. 10 (2004) 262-267).

10 Low molecular weight inhibitors for protein kinases are widely known in the state of the art. For Aurora inhibition such inhibitors are based on i.e. quinazoline derivatives as claimed in the following patents and patent applications: WO 00/44728; WO 00/47212; WO 01/21594; WO 01/21595; WO 01/21596; WO 01/21597; WO 01/77085; WO 01/55116; WO 95/19169; WO 95/23141; WO 97/42187; WO 99/06396; pyrazole and triazole derivatives as claimed in the 15 following patents and patent applications: WO 02/22601; WO 02/22602; WO 02/22603; WO 02/22604; WO 02/22605; WO 02/22606; WO 02/22607; WO 02/22608; WO 02/50065; WO 02/50066; WO 02/057259; WO 02/059112; WO 02/059111; WO 02/062789; WO 02/066461; WO 02/068415; pyrimidine derivatives: WO 03/077921; WO 03/078423; WO 03/078426; WO 03/078427; 20 WO 04/000833 or imidazole, oxazole and thiazole derivatives: WO 02/96905; WO 04/005283;

However there remains a need for structural new compounds with improved therapeutic properties, such as enhanced activity, decreased toxicity, better solubility and improved pharmacokinetic profile, to name only a few.

- 3 -

The present invention relates to the use of the compounds of the general formula I,



formula I,

wherein

5 R¹ is hydrogen, alkyl or C(O)-alkyl;

 R² is hydrogen, alkyl, cyano or halogen;

 R³ is hydrogen, alkyl, (C₃-C₆)-cycloalkyl, alkoxy or alkylsulfanyl;

 X is -C(O)- or -CH₂-;

 Y is -NH-, -CH₂-CR⁴R⁵-, -CR⁴R⁵-CH₂- or -CR⁴R⁵-, wherein

10 R⁴ is hydrogen or alkyl; and

 R⁵ is hydrogen or alkyl,
 or alternatively
 R⁴ and R⁵ form together with the carbon atom to which they are
 attached a cycloalkyl ring;

15 and all their pharmaceutically acceptable salts,

for the manufacture of medicaments for the treatment of cancer.

Another embodiment of the invention is the use of the compounds of the formula I, wherein

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl,

20 for the manufacture of medicaments for the treatment of cancer.

Another embodiment of the invention is the use of the compounds of formula I, wherein

5 as Aurora family kinase inhibitors.

Some tricycles or related compounds are known as inhibitors of erythrocyte aggregation from US 4,835,280A, EP 0 189 103, US 4,954,498 and also from Mertens, A., et al., *J. Med. Chem.* 30 (1987) 1279-1287; von der Saal, W., et al., *J. Med. Chem.* 32 (1989) 1481-1491; EP 0 318 902; DE 34 17 643; DE 36 42 315 and DE 37 01 277. US 5,212,186A describes related tricycles for the treatment of cardiac insufficiency, hypertension and other diseases.

WO 03/035065 relates to benzimidazole derivatives as kinase inhibitors, especially as inhibitors against kinase insert domain containing receptor (KDR) tyrosine kinase, spleen tyrosine kinase (SYK) and inducible T cell kinase (ITK).

15 The compounds according to this invention show activity as protein kinase inhibitors. Many diseases are associated with abnormal cellular responses triggered by protein kinase mediated events. These diseases include autoimmune diseases, inflammatory diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease or hormone-related diseases. Accordingly, there has been a substantial effort in medicinal chemistry to find protein kinase inhibitors that are effective as therapeutic agents.

20

The compounds according to this invention in particular show activity as Aurora family kinase inhibitors, especially as Aurora A kinase inhibitors, and may therefore be useful for the treatment of diseases mediated by said kinase. Aurora A inhibition leads to cell cycle arrest in the G2 phase of the cell cycle and exerts an antiproliferative effect in tumor cell lines. This indicates that Aurora A inhibitors may be useful in the treatment of i.e. hyperproliferative diseases such as cancer and in particular colorectal, breast, lung, prostate, pancreatic, gastric, bladder, ovarian, melanoma, neuroblastoma, cervical, kidney or renal cancers, leukemias or lymphomas. Treatment of acute-myelogenous leukemia (AML, acute lymphocytic leukemia (ALL) and gastrointestinal stromal tumor (GIST) is included.

Objects of the present invention are of the compounds of formula I and their tautomers, pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, their use as Aurora kinase inhibitors, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture as well as the use of the above-mentioned compounds in the control or prevention of illnesses, especially of illnesses and disorders as mentioned above or in the manufacture of corresponding medicaments.

As used herein, the term "alkyl" means a saturated, straight-chain or branched-chain hydrocarbon containing from 1 to 6, preferably 1 or 4, carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, t-butyl. Said alkyl is optionally substituted with one or several halogen atoms, preferably fluorine or chlorine, especially fluorine. Preferably the alkyl is substituted one to five times and more preferably one to three times by such halogen. Examples are trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl and the like, preferably trifluoromethyl. In one embodiment of the invention only the "alkyl" group as used in R^3 is optionally substituted by halogen while the other "alkyl" groups as used in R^1 , R^2 , R^4 and R^5 are not substituted by halogen. In another embodiment of the invention all "alkyl" groups are not substituted by halogen.

The term "alkoxy" as used herein means an alkyl group as defined above which is attached via an oxygen atom (alkyl-O-).

The term "alkylsulfanyl" as used herein means an alkyl group as defined above which is attached via an sulfur atom (alkyl-S-).

The term "cycloalkyl" as used herein means a carbocyclic unsaturated ring system containing from 3 to 6, preferably from 3 to 5, carbon atoms. Such carbocyclic unsaturated ring system can be optionally substituted one to three, preferably one or two times, especially one time by alkyl. Examples are cyclopropyl, 1-methylcycloprop-1-yl, cyclobutyl, cyclopentyl and cyclohexyl, preferably cyclopropyl. In an embodiment of the invention, the term "cycloalkyl" as used in R^3 denotes a cyclopropyl. The cycloalkyl ring which is formed by R^4 and R^5 together with the carbon atom to which they are attached is preferably a cyclopentyl or cyclohexyl ring, especially a cyclopentyl ring.

- 6 -

The term "halogen" as used herein means fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine or bromine, and more preferred fluorine and chlorine.

5

The compounds of formula I can exist in different tautomeric forms and in variable mixtures thereof. All tautomeric forms of the compounds of formula I and mixtures thereof are an objective of the invention. For example, the imidazole part of the tricyclic ring system of formula I can exist in two tautomeric forms as shown here below:



formula I

10

Also, e.g. the pyrazole ring of formula I can form two tautomeric forms as shown here below:



formula I

15

As used herein, in relation to mass spectrometry (MS) the term "API+" refers to positive atmospheric pressure ionization mode the term "API-" refers to negative atmospheric pressure ionization mode and the term "ESI+" refers to positive electrospray ionization mode.

20

An embodiment of the invention is the use of the compounds of formula I, wherein

X is $-\text{CH}_2-$;

for the manufacture of medicaments for the treatment of cancer.

- 7 -

An embodiment of the invention is the use of the compounds of formula I, wherein

R^3 is hydrogen, alkyl or (C_3 - C_6)-cycloalkyl; and

X is $-\text{CH}_2-$;

for the manufacture of medicaments for the treatment of cancer.

5 An embodiment of the invention is the use of the compounds of formula I, wherein

X is $-\text{CH}_2-$;

as Aurora family kinase inhibitors.

Another embodiment of the invention is the use of the compounds of formula I, wherein

10 X is -CH₂-; and
 Y is -CR⁴R⁵-;

for the manufacture of medicaments for the treatment of cancer.

15 Another embodiment of the invention is the use of the compounds of formula I, wherein

R^3 is hydrogen, alkyl or (C_3-C_6) -cycloalkyl;

X is $-\text{CH}_2-$; and
Y is $-\text{CR}^4\text{R}^5-$;

20 for the manufacture of medicaments for the treatment of cancer.

Another embodiment of the invention is the use of the compounds of formula I, wherein

X is $-\text{CH}_2-$; and

- 8 -

Y is $-\text{CR}^4\text{R}^5-$;

as Aurora family kinase inhibitors.

5 Still another embodiment of the invention is the use of the compounds of formula I, wherein

X is $-\text{CH}_2-$; and

Y is $-\text{NH}-$, $-\text{CH}_2\text{-CR}^4\text{R}^5-$ or $\text{CR}^4\text{R}^5\text{-CH}_2-$;

10 for the manufacture of medicaments for the treatment of cancer.

Still another embodiment of the invention is the use of the compounds of formula I, wherein

R^3 is hydrogen, alkyl or $(\text{C}_3\text{-C}_6)$ -cycloalkyl;

X is $-\text{CH}_2-$; and

15 Y is $-\text{NH}-$, $-\text{CH}_2\text{-CR}^4\text{R}^5-$ or $\text{CR}^4\text{R}^5\text{-CH}_2-$;

for the manufacture of medicaments for the treatment of cancer.

Still another embodiment of the invention is the use of the compounds of formula I, wherein

20 X is $-\text{CH}_2-$; and

Y is $-\text{NH}-$, $-\text{CH}_2\text{-CR}^4\text{R}^5-$ or $\text{CR}^4\text{R}^5\text{-CH}_2-$;

as Aurora family kinase inhibitors.

25

Yet another embodiment of the invention is the use of the compounds of formula I, wherein

X is $-\text{C}(\text{O})-$;

30 for the manufacture of medicaments for the treatment of cancer.

- 9 -

Yet another embodiment of the invention is the use of the compounds of formula I, wherein

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl; and

X is -C(O)-;

5

for the manufacture of medicaments for the treatment of cancer.

Yet another embodiment of the invention is the use of the compounds of formula I, wherein

X is -C(O)-;

10

as Aurora family kinase inhibitors.

Another embodiment of the invention is the use of the compounds of formula I, wherein

15 X is -C(O)-; and

Y is -CH₂-CR⁴R⁵- or -CR⁴R⁵-CH₂-;

for the manufacture of medicaments for the treatment of cancer.

Another embodiment of the invention is the use of the compounds of formula I, 20 wherein

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;

X is -C(O)-; and

Y is -CH₂-CR⁴R⁵- or -CR⁴R⁵-CH₂-;

25

for the manufacture of medicaments for the treatment of cancer.

Another embodiment of the invention is the use of the compounds of formula I, wherein

- 10 -

X is $-\text{C}(\text{O})-$; and
Y is $-\text{CH}_2\text{-CR}^4\text{R}^5-$ or $-\text{CR}^4\text{R}^5\text{-CH}_2-$;

as Aurora family kinase inhibitors.

5

Still another embodiment of the invention is the use of the compounds of formula I, wherein

X is $-\text{C}(\text{O})-$; and
Y is $-\text{NH-}$ or $-\text{CR}^4\text{R}^5-$;

10

for the manufacture of medicaments for the treatment of cancer.

Still another embodiment of the invention is the use of the compounds of formula I, wherein

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;

15 X is $-\text{C}(\text{O})-$; and
Y is $-\text{NH-}$ or $-\text{CR}^4\text{R}^5-$;

for the manufacture of medicaments for the treatment of cancer.

20

Still another embodiment of the invention is the use of the compounds of formula I, wherein

X is $-\text{C}(\text{O})-$; and
Y is $-\text{NH-}$ or $-\text{CR}^4\text{R}^5-$;

as Aurora family kinase inhibitors.

25

Yet another embodiment of the invention is the use of the compounds of formula I, wherein

X is $-\text{C}(\text{O})-$; and
Y is $-\text{CR}^4\text{R}^5-$;

- 11 -

for the manufacture of medicaments for the treatment of cancer.

Yet another embodiment of the invention is the use of the compounds of formula I, wherein

5 R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;

X is -C(O)-; and

Y is -CR⁴R⁵;

for the manufacture of medicaments for the treatment of cancer.

10 Yet another embodiment of the invention is the use of the compounds of formula I, wherein

X is -C(O)-; and

Y is -CR⁴R⁵;

15 as Aurora family kinase inhibitors.

Another embodiment of the invention is the use of the compounds of formula I, wherein

X is -C(O)-; and

20 Y is -NH-;

for the manufacture of medicaments for the treatment of cancer.

Another embodiment of the invention is the use of the compounds of formula I, wherein

25 R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;

X is -C(O)-; and

Y is -NH-;

for the manufacture of medicaments for the treatment of cancer.

Another embodiment of the invention is the use of the compounds of formula I, wherein

5 X is -C(O)-; and
 Y is -NH-;

as Aurora family kinase inhibitors.

10 Medicaments containing a compound of the present invention or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of the present invention and/or pharmaceutically acceptable salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

15 In accordance with the invention the compounds of the present invention as well as their pharmaceutically acceptable salts are useful in the control or prevention of illnesses. Based on their Aurora tyrosine kinase inhibition and their antiproliferative activity, said compounds are useful for the treatment of diseases such as cancer in humans or animals and for the production of corresponding medicaments. The dosage depends on various factors such as manner of administration, species, age and/or individual state of health.

20 Another embodiment of the invention is a medicament containing one or more compounds of formula I as active ingredients together with pharmaceutically acceptable adjuvants for the treatment of diseases mediated by an inappropriate activation of Aurora family tyrosine kinases, especially Aurora A tyrosine kinase.

25 Another embodiment of the invention is a medicament containing one or more compounds of formula I as active ingredients together with pharmaceutically acceptable adjuvants for the treatment of cancer.

Another embodiment of the invention is a medicament containing one or more compounds of formula I as active ingredients together with pharmaceutically acceptable adjuvants for the treatment of colorectal, breast, lung, prostate, pancreatic, gastric, bladder, ovarian, melanoma, neuroblastoma, cervical, kidney or 5 renal cancers, leukemias or lymphomas.

Another embodiment of the invention is a medicament containing one or more compounds of formula I as active ingredients together with pharmaceutically acceptable adjuvants for the treatment of acute-myelogenous leukemia (AML), acute lymphocytic leukemia (ALL) and gastrointestinal stromal tumor (GIST).

10 Another embodiment of the invention is the use of one or more compounds of formula I for the manufacture of medicaments for the treatment of diseases mediated by an inappropriate activation of Aurora family tyrosine kinases.

Another embodiment of the invention is the use of the compounds of formula I as Aurora A tyrosine kinase inhibitors.

15 Another embodiment of the invention is the use of the compounds of formula I as anti-proliferating agents.

Another embodiment of the invention is the use of one or more compounds of formula I for the treatment of cancer.

20 Another embodiment of the invention is the use of one or more compounds of formula I for the manufacture of medicaments for the treatment of diseases mediated by an inappropriate activation of Aurora family tyrosine kinases.

Another embodiment of the invention is the use of one or more compounds of formula I for the manufacture of medicaments for the treatment for the treatment of cancer.

25 Another embodiment of the invention is the use of one or more compounds of formula I for the manufacture of medicaments for the treatment of colorectal, breast, lung, prostate, pancreatic, gastric, bladder, ovarian, melanoma, neuroblastoma, cervical, kidney or renal cancers, leukemias or lymphomas

- 14 -

Another embodiment of the invention is the use of one or more compounds of formula I for the manufacture of medicaments for the treatment of acute-myelogenous leukemia (AML, acute lymphocytic leukemia (ALL) and gastrointestinal stromal tumor (GIST). Another embodiment of the invention is a medicament containing one or more compounds of formula I as active ingredients together with pharmaceutically acceptable adjuvants for the treatment of diseases mediated by an inappropriate activation of Aurora family tyrosine kinases, especially Aurora A tyrosine kinase.

Another embodiment of the invention is a medicament containing one or more compounds of formula I as active ingredients together with pharmaceutically acceptable adjuvants for the treatment of cancer.

Another embodiment of the invention is a medicament containing one or more compounds of formula I as active ingredients together with pharmaceutically acceptable adjuvants for the treatment of colorectal, breast, lung, prostate, pancreatic, gastric, bladder, ovarian, melanoma, neuroblastoma, cervical, kidney or renal cancers, leukemias or lymphomas.

Another embodiment of the invention is a medicament containing one or more compounds of formula I as active ingredients together with pharmaceutically acceptable adjuvants for the treatment of acute-myelogenous leukemia (AML, acute lymphocytic leukemia (ALL) and gastrointestinal stromal tumor (GIST).

Another embodiment of the invention are the compounds of formula I, wherein

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;

with the proviso that, if R¹ and R² are hydrogen, X is -C(O)- and Y is -CR⁴R⁵-;
25 wherein R⁴ and R⁵ are methyl;

then R³ is hydrogen, (C₂-C₆)alkyl or (C₃-C₆)-cycloalkyl.

Still another embodiment of the invention are the compounds of formula I, wherein

30 R³ is hydrogen, (C₂-C₆)alkyl or (C₃-C₆)-cycloalkyl.

- 15 -

Another embodiment of the invention are the compounds of formula I, wherein

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl; and

X is -CH₂-.

Still another embodiment of the invention are the compounds of formula I,

5 wherein

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;

X is -CH₂-; and

Y is -CR⁴R⁵-.

10 Such compounds are for example:

7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-3,5,6,7-tetrahydro-imidazo[4,5-f]indole; and

1-[7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-6,7-dihydro-3H-imidazo[4,5-f]indol-5-yl]-ethanone.

15 Another embodiment of the invention are the compounds of formula I, wherein

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;

X is -CH₂-; and

Y is -NH-, -CH₂-CR⁴R⁵- or -CR⁴R⁵-CH₂-.

20 Still another embodiment of the invention are the compounds of formula I, wherein

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl; and

X is -C(O)-;

- 16 -

with the proviso that, if R^1 and R^2 are hydrogen, X is $-C(O)-$ and Y is $-CR^4R^5-$;
wherein R^4 and R^5 are methyl;

then R^3 is hydrogen, (C_2-C_6) alkyl or (C_3-C_6) -cycloalkyl.

5 Still another embodiment of the invention are the compounds of formula I,
wherein

R^3 is hydrogen, (C_2-C_6) alkyl or (C_3-C_6) -cycloalkyl; and
X is $-C(O)-$.

10 Still another embodiment of the invention are the compounds of formula I,
wherein

R^3 is hydrogen, alkyl or (C_3-C_6) -cycloalkyl;
X is $-C(O)-$; and
Y is $-CH_2-CR^4R^5-$ or $-CR^4R^5-CH_2-$.

15 Such compounds are for example:

8,8-Dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one; and

20 2-(5-Isobutyl-2H-pyrazol-3-yl)-8,8-dimethyl-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one.

Another embodiment of the invention are the compounds of formula I, wherein

R^3 is hydrogen, alkyl or (C_3-C_6) -cycloalkyl;
X is $-C(O)-$; and
Y is $-NH-$, $-CR^4R^5-$;

25 with the proviso that, if R^1 and R^2 are hydrogen, X is $-C(O)-$ and Y is $-CR^4R^5-$;
wherein R^4 and R^5 are methyl;

- 17 -

then R³ is hydrogen, (C₂-C₆)alkyl or (C₃-C₆)-cycloalkyl.

Another embodiment of the invention are the compounds of formula I, wherein

5 R³ is hydrogen, (C₂-C₆)alkyl or (C₃-C₆)-cycloalkyl;
 X is -C(O)-; and
 Y is -NH-, -CR⁴R⁵-.

Still another embodiment of the invention are the compounds of formula I, wherein

10 R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;
 X is -C(O)-; and
 Y is -CR⁴R⁵-;

15 with the proviso that, if R¹ and R² are hydrogen, X is -C(O)- and Y is -CR⁴R⁵-;
 wherein R⁴ and R⁵ are methyl;

then R³ is hydrogen, (C₂-C₆)alkyl or (C₃-C₆)-cycloalkyl.

Still another embodiment of the invention are the compounds of formula I, wherein

20 R³ is hydrogen, (C₂-C₆)alkyl or (C₃-C₆)-cycloalkyl.
 X is -C(O)-; and
 Y is -CR⁴R⁵-.

Such compounds are for example:

25 2-(5-Isobutyl-2H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

2-(5-methyl-2H-pyrazol-3-yl)-spiro[7,7-cyclopentan-5,7-dihydro-3H-imidazo[4,5-f]indol]-6-one; or according to actual IUPAC nomenclature 2-(5-Methyl-2H-

- 18 -

pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one;

2-(5-Isobutyl-2H-pyrazol-3-yl)-spiro[7,7-cyclopentan-5,7-dihydro-1H-imidazo[4,5-f]indol]-6-one; or according to actual IUPAC nomenclature 2-(5-Isobutyl-2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one;

5-Ethyl-7,7-dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5,7,7-Trimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-2-(5-isobutyl-2H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one; and

15 2-(5-Isobutyl-2H-pyrazol-3-yl)-5,7,7-trimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one.

Another embodiment of the invention are the compounds of formula I, wherein

R^3 is hydrogen, alkyl or (C_3-C_6) -cycloalkyl;

X is -C(O)-; and

20 Y is -NH-.

Such compounds are for example:

6-(5-Methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one;

- 19 -

3-Methyl-6-(5-methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one; and

3-Isopropyl-6-(5-methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one.

5 Another embodiment of the invention are the compounds of formula I, wherein

R^1 is alkyl or $-C(O)-alkyl$.

Another embodiment of the invention are the compounds of formula I, wherein

R^1 is alkyl.

10 Another embodiment of the invention are the compounds of formula I, wherein

R^1 is alkyl; and

R^2 is hydrogen or alkyl.

Another embodiment of the invention are the compounds of formula I, wherein

R^1 is alkyl;

15 R^2 is hydrogen or alkyl; and

R^3 is hydrogen, alkyl or (C_3-C_6) -cycloalkyl.

Another embodiment of the invention are the compounds of formula I, wherein

R^1 is alkyl;

X is $-C(O)-$; and

20 Y is $-CH_2-CR^4R^5-$, $-CR^4R^5-CH_2-$ or $-CR^4R^5-$.

- 20 -

Another embodiment of the invention are the compounds of formula I, wherein

R¹ is alkyl;

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;

X is -C(O)-; and

5 Y is -CH₂-CR⁴R⁵-, -CR⁴R⁵-CH₂- or -CR⁴R⁵-.

Another embodiment of the invention are the compounds of formula I, wherein

R¹ is alkyl;

R² is hydrogen or alkyl;

X is -C(O)-; and

10 Y is -CR⁴R⁵-.

Another embodiment of the invention are the compounds of formula I, wherein

R¹ is alkyl;

R² is hydrogen;

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;

15 X is -C(O)-; and

Y is -CR⁴R⁵-.

Such compounds are for example:

5-Ethyl-7,7-dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

- 21 -

5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5,7,7-Trimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5 5-Ethyl-2-(5-isobutyl-2H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

2-(5-Isobutyl-2H-pyrazol-3-yl)-5,7,7-trimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5,7,7-Trimethyl-2-(1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

10 5,7,7-Trimethyl-2-(5-methyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-7,7-dimethyl-2-(1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

15 5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one; compound with acetic acid;

5-Isopropyl-7,7-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

5-Isopropyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

20 7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5-propyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

7,7-Dimethyl-5-propyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

Another embodiment of the invention are the compounds of formula I, wherein

- 22 -

R¹ is alkyl;

R² is hydrogen or alkyl;

R³ is alkyl which is substituted one or several times by halogen;

X is -C(O)-; and

5 Y is -CR⁴R⁵-.

Such compounds are for example:

5-Ethyl-7,7-dimethyl-2-(5-trifluoromethyl-1*H*-pyrazol-3-yl)-5,7-dihydro-3*H*-imidazo[4,5-*f*]indol-6-one;

10 5-Isopropyl-7,7-dimethyl-2-(5-trifluoromethyl-2*H*-pyrazol-3-yl)-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

7,7-Dimethyl-5-propyl-2-(5-trifluoromethyl-2*H*-pyrazol-3-yl)-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one; and

5,7,7-Trimethyl-2-(5-trifluoromethyl-2*H*-pyrazol-3-yl)-5,7-dihydro-3*H*-imidazo[4,5-*f*]indol-6-one.

15

Another embodiment of the invention are the compounds of formula I, wherein

R¹ is alkyl;

R² is hydrogen or alkyl;

R³ is alkoxy or alkylsulfanyl;

20 X is -C(O)-; and

- 23 -

Y is $-\text{CR}^4\text{R}^5-$.

Such compounds are for example:

5-Ethyl-2-(5-methoxy-1H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one; and

5 5-Ethyl-7,7-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one

Another embodiment of the invention are the compounds of formula I, wherein

R^1 is alkyl;

R^2 is hydrogen or alkyl;

10 R^3 is hydrogen, alkyl or $(\text{C}_3\text{-C}_6)$ -cycloalkyl;

X is $-\text{C}(\text{O})-$; and

Y is $-\text{CH}_2\text{-CR}^4\text{R}^5-$ or $\text{CR}^4\text{R}^5\text{-CH}_2-$.

Another embodiment of the invention are the compounds of formula I, wherein

R^1 is alkyl;

15 R^2 is hydrogen or alkyl;

R^3 is hydrogen, alkyl or $(\text{C}_3\text{-C}_6)$ -cycloalkyl;

X is $-\text{C}(\text{O})-$; and

Y is $-\text{NH}-$.

Such compounds are for example:

- 24 -

3-Methyl-6-(5-methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one; and

3-Isopropyl-6-(5-methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one.

5 Another embodiment of the invention are the compounds of formula I, wherein

R^1 is $-C(O)-alkyl$;

R^2 is hydrogen or alkyl;

R^3 is hydrogen, alkyl or (C_3-C_6) -cycloalkyl;

X is $-CH_2-$; and

10 Y is $-CH_2-CR^4R^5-$, $-CR^4R^5-CH_2-$ or $-CR^4R^5-$.

Such a compound is for example:

1-[7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-6,7-dihydro-3H-imidazo[4,5-f]indol-5-yl]-ethanone.

15 Another embodiment of the invention is a medicament containing one or more compounds of formula I, with the proviso that, if R^1 and R^2 are hydrogen, X is $C(O)-$ and Y is $-CR^4R^5-$; wherein R^4 and R^5 are methyl; then R^3 is hydrogen, (C_2-C_6) alkyl or (C_3-C_6) -cycloalkyl, as active ingredients together with pharmaceutically acceptable adjuvants

20 Another embodiment of the invention is a medicament containing one or more compounds of formula I, wherein R^3 is hydrogen, (C_2-C_6) alkyl, (C_3-C_6) -cycloalkyl or fluorine, as active ingredients together with pharmaceutically acceptable adjuvants

Another embodiment of the invention is a medicament containing one or more compounds of formula I, wherein R¹ is alkyl or -C(O)-alkyl, as active ingredients together with pharmaceutically acceptable adjuvants.

5 Another embodiment of the invention is a medicament containing one or more compounds of formula I, wherein R¹ is alkyl, as active ingredients together with pharmaceutically acceptable adjuvants.

Another embodiment of the invention is the use of one of the following compounds for the manufacture of a medicament for the treatment of cancer:

10 7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-3,5,6,7-tetrahydro-imidazo[4,5-f]indole;

1-[7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-6,7-dihydro-3H-imidazo[4,5-f]indol-5-yl]-ethanone;

15 8,8-Dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one;

2-(5-Isobutyl-2H-pyrazol-3-yl)-8,8-dimethyl-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one;

20 7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

2-(5-Isobutyl-2H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

25 2-(5-methyl-2H-pyrazol-3-yl)-spiro[7,7-cyclopentan-5,7-dihydro-3H-imidazo[4,5-f]indol]-6-one; or according to actual IUPAC nomenclature 2-(5-methyl-2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one;

2-(5-Isobutyl-2H-pyrazol-3-yl)-spiro[7,7-cyclopentan-5,7-dihydro-1H-imidazo[4,5-f]indol]-6-one; or according to actual IUPAC nomenclature 2-(5-

- 26 -

Isobutyl-2*H*-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-*f*]indol]-6(3*H*)-one;

6-(5-Methyl-1*H*-pyrazol-3-yl)-3,5-dihydro-1*H*-benzo[1,2-*d*;4,5-*d*']diimidazol-2-one;

5 2-(4,5-Dimethyl-1*H*-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

7,7-Dimethyl-2-[5-(3-methyl-butyl)-1*H*-pyrazol-3-yl]-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

10 2-(5-Ethyl-4-methyl-1*H*-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

7,7-Dimethyl-2-(1*H*-pyrazol-3-yl)-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

2-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

15 2-(5-Isopropyl-2*H*-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

8,8-Dimethyl-2-(5-propyl-2*H*-pyrazol-3-yl)-1,5,7,8-tetrahydro-imidazo[4,5-*g*]quinolin-6-one;

8,8-Dimethyl-2-(1*H*-pyrazol-3-yl)-1,5,7,8-tetrahydro-imidazo[4,5-*g*]quinolin-6-one;

20 2-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-8,8-dimethyl-1,5,7,8-tetrahydro-imidazo[4,5-*g*]quinolin-6-one

2-(5-Isopropyl-2*H*-pyrazol-3-yl)-8,8-dimethyl-1,5,7,8-tetrahydro-imidazo[4,5-*g*]quinolin-6-one;

- 27 -

2-(2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one;

2-(5-Isopropyl-2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one;

5 2-(5-Propyl-2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one;

7,7-Dimethyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one; and

10 2-(5-Cyclopropyl-2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one.

Another embodiment of the invention is the use of one of the following compounds for the manufacture of a medicament for the treatment of cancer:

15 3-Methyl-6-(5-methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one;

15 3-Isopropyl-6-(5-methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one;

5-Ethyl-7,7-dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

20 5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5,7,7-Trimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-2-(5-isobutyl-2H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

- 28 -

2-(5-Isobutyl-2H-pyrazol-3-yl)-5,7,7-trimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5,7,7-Trimethyl-2-(1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5,7,7-Trimethyl-2-(5-methyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-7,7-dimethyl-2-(1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one; compound with acetic acid;

5-Isopropyl-7,7-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

5-Isopropyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5-propyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

7,7-Dimethyl-5-propyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-7,7-dimethyl-2-(5-trifluoromethyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Isopropyl-7,7-dimethyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

7,7-Dimethyl-5-propyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

- 29 -

5,7,7-Trimethyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;


5-Ethyl-2-(5-methoxy-1H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one; and

5 5-Ethyl-7,7-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

Another embodiment of the invention is a process for the preparation of the compounds of formula I, wherein

10 R¹ is alkyl or -C(O)-alkyl;
by


a) reacting a compound of formula II



formula II,

15 wherein R¹ is alkyl or -C(O)-alkyl and X and Y have the significance given above for formula I;


with a compound of formula III,



20 formula III,

wherein A is -OH, -Cl, -H or -OMe and R² and R³ have the significance given above for formula I;

25 to give the compounds of formula I,



5 wherein R¹ is alkyl or -C(O)-alkyl and R², R³, X and Y have the significance given above for formula I;


- 10 b) isolating said compound of formula I from the reaction mixture, and
- 10 c) if desired, converting it into a pharmaceutically acceptable salt.

The compounds of formula I, or a pharmaceutically acceptable salt thereof, which are subject of the present invention may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, 15 when used to prepare a compound of the formula I, or a pharmaceutically-acceptable salt thereof, are illustrated by the following representative schemes 1 and 2 and examples in which, unless otherwise stated, X, Y, R¹, R² and R³ have the significance given herein before. Necessary starting materials may be obtained by standard 20 procedures of organic chemistry. The preparation of such starting materials is described within the accompanying examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.

The benzimidazole ring system of formula I can be formed by different synthetic pathways in analogy to methods described in the literature (Mertens, A., et al., J. 25 Med. Chem. 30 (1987) 1279-1287; DE 35 31 678).


One route for the preparation of compounds of formula I (Scheme 1) starts from diamines of formula II which can be reacted with carboxylic acids (compounds of formula III wherein A is OH), acid chlorides (A is Cl), aldehydes (A is H), methyl 30 carboxylates (A is OMe) or activated esters (A is e.g. hydroxybenzotriazole). For detailed procedures see the literature cited above.

- 31 -

Scheme 1

Pyrazoles of formula III are commercially available or they can be prepared by standard procedures of organic chemistry (see e.g. Stanovnik, B., and Svetec, J., 5 Science of Synthesis 12 (2002) 15-225), e.g. condensation of a 1,3-dicarbonyl compound with hydrazine (see e.g. WO 04/032928 or van Herk, T., et al., J. Med. Chem. 46 (2003) 3945-3951) or 1,3-dipolar cycloaddition between a diazo compound and an acetylene (see e.g. Sewald, N., et al., Liebigs Ann. Chem. (1992) 947-952). Pyrazoles of formula III wherein R³ is alkoxy can be prepared either via 10 the 5-hydroxy-pyrazole-3-carboxylic acid esters (see e.g. Ochi, H. et al., Chem. Pharm. Bull. 31 (1983) 1228-1234) with subsequent O-alkylation of the 5-hydroxy group with alkylhalogenides in the presence of a base such as caesium carbonate and the like in solvents such as dimethylformamide (DMF), N-methyl-pyrrolidinone (NMP) and the like (see e.g. WO 03/035065) or according to the 15 procedure of Martins, M.A.P., et al., Synthesis 15 (2003) 2353-2357. And pyrazoles of formula III wherein R³ is alkylsulfanyl can be prepared via the corresponding oxo-ketene dithioacetals according to Mahata, P.K., et al., Tetrahedron 59 (2003) 2631-2639. Alternatively to Scheme 1, the 5-alkoxy- or 5-alkylsulfanyl-pyrazole 20 moieties of compounds of formula I, wherein R³ is alkoxy or alkylsulfanyl, can be introduced by another sequence of reaction steps as described in WO 03/035065. Pyrazoles of formula III wherein R² is hydrogen, R³ is trifluoromethyl and A is 25 hydroxy can be prepared in a three step procedure according to Scheme 1a: condensation of 4,4,4-trifluoro-1-(2-furyl)-1,3-butanedione with benzyl hydrazine under acidic conditions, oxidative degradation of the furan ring with potassium permanganate to the carboxylic acid functionality (see e.g. Djuric, S.W., et al., J. Med. Chem. 43 (2000) 2975-2981; Jia, Z.J., et al., Bioorg. Med. Chem. Lett. 12 (2002) 1651-1655 or Pruitt, J.R., et al., J. Med. Chem. 46 (2003) 5298-5315) and cleavage of the benzyl protecting group provides the desired 5-trifluoromethyl-2H-pyrazole-3-carboxylic acid.

- 32 -

**Scheme 1a**

This procedure involving the N-benzyl or alternatively the p-methoxybenzyl group (Subramanyam, C., *Synth. Commun.* 25 (1995) 761-774 as intermediate protecting group can be also applied for preparing other pyrazoles needed as starting material.


10

Compounds of formula II wherein X is -C(O)-, R¹ is hydrogen or alkyl and Y is -CR⁴R⁵ or -NH- can be prepared in an analogous manner as described in Mertens, A., et al., *J. Med. Chem.* 30 (1987) 1279-1287; von der Saal, W., et al., *J. Med. Chem.* 32 (1989) 1481-1491; DE 34 17 643; EP 0 318 902, US 4,666,923A, US 4,695,567A, US 4,863,945A and US 4,985,448A.. Compounds of formula II wherein X is -C(O)- or -CH₂-, R¹ is hydrogen or -C(O)alkyl and Y is -CR⁴R⁵- can be prepared according to DE 36 42 315. And furthermore the compounds of formula II wherein X is -C(O)- or -CH₂-, R¹ is hydrogen or alkyl and Y is -CR⁴R⁵-CH₂- or -CH₂-CR⁴R⁵- are described in DE 37 01 277.

15

For instance, the diamines of formula II, wherein X is -C(O)-, R¹ is hydrogen or alkyl and Y is -CR⁴R⁵, are named IIa and can be synthesized according to US 4,666,923A, DE 34 10 168 and Mertens, A., et al., *J. Med. Chem.* 30 (1987) 1279-1287 as shown in Scheme 1b:

- 33 -

Scheme 1b

In scheme 1b, R¹, R⁴ and R⁵ have the significance as given above for formula I and L represents a leaving group as e.g. iodine, bromine, chlorine, triflate and the like.


5 In an alternative procedure diamines of formula IIa, wherein R¹ is alkyl, can be obtained by an alkylation of diamines of formula IIb (compounds II wherein X is -C(O)-, R¹ is hydrogen and Y is -CR⁴R⁵.) as shown in scheme 1c.

Scheme 1c

10 Diamines of formula IIb can be synthesized according to scheme 1b under omission of step 5.

Another synthesis of compounds of formula I (Scheme 2) starts from nitro compounds IV or V which are hydrogenated and subsequently cyclized with acetic acid or hydrochloric acid to the desired benzimidazole derivative. For detailed procedures see Mertens, A., et al., J. Med. Chem. 30 (1987) 1279-1287; DE 35 31 678.

- 34 -



Scheme 2

Compounds of formulas IV and V wherein X is C(O), R¹ is hydrogen or alkyl and Y is -CR⁴R⁵, -NH- can be prepared in an analogous manner as described in Mertens, A., et al., J. Med. Chem. 30 (1987) 1279-1287; von der Saal, W., et al., J. Med. Chem. 32 (1989) 1481-1491; DE 34 17 643; EP 0 318 902. Compounds of formulas IV and V with wherein X is C(O) or -CH₂-, R¹ is hydrogen or -C(O)alkyl and Y is -CR⁴R⁵- can be prepared according to DE 36 42 315. And furthermore the compounds of formula II wherein X is C(O) or -CH₂-, R¹ is hydrogen or alkyl and Y is -CR⁴R⁵-CH₂- or -CH₂-CR⁴R⁵- are described in DE 37 01 277.

The compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to conventional acid-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids. Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, methanesulfonic acid, ethanesulfonic acid and the like. The chemical modification of a pharmaceutical compound (i.e. a drug) into a salt is a technique well known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See

e.g. Stahl, P.H., and Wermuth, G., (editors), *Handbook of Pharmaceutical Salts*, Verlag Helvetica Chimica Acta (VHCA) Zürich, (2002) or Bastin, R.J., et al., *Organic Proc. Res. Dev.* 4 (2000) 427-435 .

5 The compounds of formula I can contain one or several chiral centers and can then be present in a racemic or in an optically active form. The racemates can be separated according to known methods into the enantiomers. For instance, diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-10 camphorsulfonic acid. Alternatively separation of the enantiomers can also be achieved by using chromatography on chiral HPLC-phases which are commercially available.

Pharmacological activity

15 The compounds of formula I and their pharmaceutically acceptable salts possess valuable pharmacological properties. It has been found that said compounds show activity as inhibitors of the Aurora kinase family and also show anti-proliferative activity. Consequently the compounds of the present invention are useful in the therapy and/or prevention of illnesses with known over-expression of kinases of the Aurora family preferably Aurora A, especially in the therapy and / or prevention of 20 illnesses mentioned above. The activity of the present compounds as inhibitors of the Aurora kinase family is demonstrated by the following biological assay:

IC₅₀ determination for inhibitors of Aurora A

(96 MTP-ELISA)

Assay principle

25 Aurora A is a serine threonine kinase involved in spindle assembly and chromosome segregation.

The assay is a typically ELISA-type assay where biotinylated substrate (PKB-GSK2) is phosphorylated. Phosphorylation is detected by peroxidase (POD) labelled polyclonal antibody (PAK<M-Ig>S-IgG-POD) and phosphopeptide monoclonal

antibody (Mab) (MAK<P-GSK>M-27E5-IgG). The assay is validated for IC₅₀ - determination.

Materials

| | | |
|----|----------------------|--|
| | Assay plates | 96-well polystyrene plates, streptavidin-coated, |
| 5 | Samples | 10 mM in dimethylsulfoxide (DMSO) |
| | Aurora A-His-4 | C-terminally Histidine ₄ (His ₄)-tagged Aurora A full-length protein, stock solution 0,7 mg/ml, final conc.: 250ng/ml |
| 10 | PKB-GSK2 | biotinylated peptide derived from human GSK3-alpha sequence (Biotin-SGRARTSSFAEPGG-CONH ₂), stock solution 600μM, final conc.: 200 nM |
| | PAK<M-Ig>S-IgG- POD | Anti-mouse IgG, horse radish peroxidase(HRP)-linked Antibody, diluted in 3% BSA/PBS-T (1:10000), (Cell Signaling, Cat. No.: 7076) |
| 15 | MAK<P-GSK>M-27E5-IgG | Phospho-GSK-3-alpha (Ser 21) (27E5) Monoclonal Antibody, stock solution 1,85mg/ml, diluted in 3% BSA/PBS-T (1:6000), final conc.: 0,31μg/ml, (Cell Signaling, Cat. No.: 9337B) |
| 20 | ATP | Adenosine-5'-triphosphate 1 mM, diluted in kinase buffer, (Roche Diagnostics GmbH, Cat. No.: 127531-001,), final conc.: 4μM |
| 25 | TRIS | 2-Amino-2-hydroxymethyl-1,3-propoanediol ("tris-(hydroxymethyl)-aminomethane") (MERCK, Cat. No.: 108382.2500) |
| | BSA | Bovine Serum Albumin Fraction V, fatty acid free (Roche Diagnostics GmbH, Cat. No. 9100221) |
| | EDTA | Titriplex III (di-Sodium-EDTA di-Hydrate), 120 mM, (MERCK, Cat. No.: 1.08418.1000) |
| 30 | ABTS buffer | ABTS (2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid))16,7 mg/ml (Roche Diagnostics GmbH, Cat. No.: 1204530) |

- 37 -

| | | |
|----|---------------------------------------|---|
| | ABTS tablets | dissolve one ABTS tablet in 50 ml of working solution (ABTS buffer) (Roche Diagnostics GmbH, Cat. No.: 1112422) |
| 5 | Tween 20 | Polysorbat 20 (Roche Diagnostics GmbH, Cat. No.: 10006394-001) |
| | DTT | 1,4-Dithiothreitol (Roche Diagnostics GmbH, Cat. No.: 197777) |
| | MgCl ₂ x 6H ₂ O | MERCK, Cat. No.: 105833.1000 |
| 10 | Kinase buffer | 50 mM TRIS, 10 mM MgCl ₂ , 1 mM DTT, 0,1% Tween 20, pH 7,8 |
| | PBS-T (= Wash buffer) | (PBS-T) 10 g/l PBS(Phosphate buffered saline) with 0,033% Tween 20 |
| | 3% BSA/PBS-T | 3 % BSA dissolved in PBS-T |
| 15 | <u>Method</u> | |

This assay is performed in 96-well format for IC₅₀ determination with 5 samples

(each with 8 concentrations by twofold testing), 100 µl incubation volume and the following plate layout:

- 38 -

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|----|------|------|-----|-----|-----|-----|----|-----|-----|-----|-----|
| A | NC | RS a | RS a | S1a | S1a | S2a | S2a | NC | S3a | S3a | S4a | S4a |
| B | NC | RS b | RS b | S1b | S1b | S2b | S2b | NC | S3b | S3b | S4b | S4b |
| C | NC | RS c | RS c | S1c | S1c | S2c | S2c | NC | S3c | S3c | S4c | S4c |
| D | NC | RS d | RS d | S1d | S1d | S2d | S2d | NC | S3d | S3d | S4d | S4d |
| E | PC | RS e | RS e | S1e | S1e | S2e | S2e | PC | S3e | S3e | S4e | S4e |
| F | PC | RS f | RS f | S1f | S1f | S2f | S2f | PC | S3f | S4f | S4f | S4f |
| G | PC | RS g | RS g | S1g | S1g | S2g | S2g | PC | S3g | S4g | S4g | S4g |
| H | PC | RS h | RS h | S1h | S1h | S2h | S2h | PC | S3h | S4h | S4h | S4h |

NC negative control, without ATP, 1% DMSO

PC positive control, with ATP, 1% DMSO

S samples, with ATP, 1 % DMSO, final conc.: a =100 μ M, b =20 μ M, c =4 μ M, d =0.8 μ M, e =0.16 μ M, f =0.032 μ M, g =0.0064 μ M, h =0.00128 μ M5 Step / Action

1. Sample preparation: add 24 μ l per well samples (descending sequence) diluted in kinase buffer to assay plate (final conc. for DMSO 1%).
2. Add directly 16 μ l Aurora-A-his-4 diluted in kinase buffer to assay plate.
3. Add directly 40 μ l per well PKB-GSK2/ATP mixture to assay plate, (final conc.: Aurora A = 250 ng/ml, GSK2 = 200 nM, ATP = 4 μ M).
- 10 4. Negative control: without ATP.
5. Incubate assay plate for exactly 90 min at room temperature.
6. Stop reaction by adding 20 μ l EDTA in all wells.
7. Wash assay plate 3 x with 200 μ l washing buffer per well.
- 15 8. Add 100 μ l MAK<P-GSK>M27E5-IgG (1:10000) and PAK<M-Ig>S-IgG-POD (1:6000) dissolved in 3% BSA/PBS-T to assay plate per well.
9. Incubate assay plate for 60 min at room temperature.
10. Wash assay plate 3 x with 200 μ l washing buffer per well
- 20 11. Add 100 μ l ABTS solution to assay plate per well, incubate for approx. 4 min at RT on MTP shaker.

- 39 -

11. Measure absorption at 405/492 nm.

12. Calculate % inhibition as:

$$(1 - (E_{\text{sample}} - E_{\text{NC}}) / (E_{\text{PC}} - E_{\text{NC}})) \times 100$$

5 13. Calculate IC₅₀ using a non-linear curve fit (XLfit software (ID Business Solution Ltd., Guilford, Surrey, UK))

Results: Table 1

| Examples | IC ₅₀ Aurora A kinase inhibition [nM] |
|--|--|
| 11 | 158 |
| 3 | 212 |
| 2, 5, 7, 10, 17, 18, 19, 21, 23, 25, 27, 31, 34, 35, 36, 37 | 10-500 |
| 4, 6, 9, 24, 28, 29, 41 | 500-1500 |

Antiproliferative activity

10 The activity of the present compounds as antiproliferative agents is demonstrated by the following biological assay:

CellTiter-GloTM assay in HCT 116 cells

15 The CellTiter-GloTM Luminescent Cell Viability Assay (Promega) is a homogeneous method of determining the number of viable cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells.

20 HCT 116 cells (human colon carcinoma, ATCC-No. CCL-247) were cultivated in RPMI 1640 medium with GlutaMAXTM I (Invitrogen, Cat-No. 61870-010), 2,5 % Fetal Calf Serum (FCS, Sigma Cat-No. F4135 (FBS)); 100Units/ml penicillin/100µg/ml streptomycin (= Pen/Strep from Invitrogen Cat.No. 15140). For the assay the cells were seeded in 384 well plates, 1000 cells per well, in the same medium. The next day the test compounds were added in various concentrations ranging from 30 µM to 0.0015 µM (10 concentrations, 1:3 diluted). After 5 days the CellTiter-GloTM assay was done according to the instructions of the manufacturer

- 40 -

(CellTiter-GloTM Luminescent Cell Viability Assay, from Promega). In brief: the cell-plate was equilibrated to room temperature for approximately 30 minutes and than the CellTiter-GloTM reagent was added. The contents were carefully mixed for 15 minutes to induce cell lysis. After 45 minutes the luminescent signal was measured in Victor 2, (scanning multiwell spectrophotometer, Wallac).

5

Details:

1st. day:

- Medium: RPMI 1640 with GlutaMAXTM I (Invitrogen, Cat-Nr. 61870), 5 % FCS (Sigma Cat.-No. F4135), Pen/Strep (Invitrogen, Cat No. 15140).
- 10 - HCT116 (ATCC-No. CCL-247): 1000 cells in 60 µl per well of 384 well plate (Greiner 781098, µClear-plate white)
- After seeding incubate plates 24 h at 37°C, 5% CO₂

2nd. day : Induction (Treatment with compounds, 10 concentrations):

15 In order to achieve a final concentration of 30 µM as highest concentration 3,5 µl of 10 mM compound stock solution were added directly to 163 µl media. Then step e) of the dilution procedure described below, was followed.

20 In order to achieve the second highest to the lowest concentrations, a serial dilution with dilution steps of 1:3 was followed according to the procedure (a -e) as described here below:

- a) for the second highest concentration add 10 µl of 10 mM stock solution of compound to 20 µl dimethylsulfoxide (DMSO)
- b) dilute 8x 1:3 (always 10 µl to 20 µl DMSO) in this DMSO dilution row (results in 9 wells with concentrations from 3333,3 µM to 0.51 µM)
- 25 c) dilute each concentration 1: 47,6 (3,5 µl compound dilution to 163 µl media)
- e) add 10 µl of every concentration to 60 µl media in the cell plate resulting in final concentration of DMSO : 0.3 % in every well and resulting in 10 final concentration of compounds ranging from 30 µM to 0.0015 µM.

30

- 41 -

- Each compound is tested in triplicate.
- Incubate 120 h (5 days) at 37°C, 5% CO₂

Analysis:

5 -Add 30 µl CellTiter-GloTM Reagent (prepared from CellTiter-GloTM Buffer and CellTiter-GloTM Substrate (lyophilized) purchased from Promega) per well,
 -shake 15 minutes at room temperature
 -incubate further 45 minutes at room temperature without shaking

10 Measurement:

-Victor 2 scanning multiwell spectrophotometer (Wallac), Luminescence mode (0.5 sec/read, 477 nm)
 15 -Determine IC₅₀ using a non-linear curve fit (XLfit software (ID Business Solution Ltd., Guilford, Surrey, UK))

With all compounds a significant inhibition of HCT 116 cell viability was detected, which is exemplified by the compounds shown in Table 1.

Results: Table 2

| Examples | IC ₅₀ HCT 116 [µM] |
|--|-------------------------------|
| 42 | 0.98 |
| 14 | 1.20 |
| 2 | 4.67 |
| 4 | 7.65 |
| 5, 6, 7, 8, 12, 13, 15, 16, 17, 18, 20, 22, 23, 24, 27, 28, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 43, 44, 45 | 0.1-10.0 |
| 3, 9, 11, 38 | 10.0-100 |

20

The compounds according to this invention and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions.

- 42 -

The pharmaceutical compositions can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

5 The above-mentioned pharmaceutical compositions can be obtained by processing the compounds according to this invention with pharmaceutically inert, inorganic or organic carriers. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

10

15

The pharmaceutical compositions can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

20 A pharmaceutical compositions comprise e.g. the following:

a) Tablet Formulation (Wet Granulation):

| Item | Ingredients | mg/tablet | | | |
|------|----------------------------|-----------|-----|-----|-----|
| 1. | Compound of formula (I) | 5 | 25 | 100 | 500 |
| 2. | Lactose Anhydrous DTG | 125 | 105 | 30 | 150 |
| 3. | Sta-Rx 1500 | 6 | 6 | 6 | 30 |
| 4. | Microcrystalline Cellulose | 30 | 30 | 30 | 150 |
| 5. | Magnesium Stearate | 1 | 1 | 1 | 1 |
| | Total | 167 | 167 | 167 | 831 |

Manufacturing Procedure:

1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.
3. Pass the granules through suitable milling equipment.
5. 4. Add item 5 and mix for three minutes; compress on a suitable press.

b) Capsule Formulation:

| Item | Ingredients | mg/capsule | | | |
|------|-------------------------|------------|-----|-----|-----|
| 1. | Compound of formula (I) | 5 | 25 | 100 | 500 |
| 2. | Hydrous Lactose | 159 | 123 | 148 | --- |
| 3. | Corn Starch | 25 | 35 | 40 | 70 |
| 4. | Talc | 10 | 15 | 10 | 25 |
| 5. | Magnesium Stearate | 1 | 2 | 2 | 5 |
| | Total | 200 | 200 | 300 | 600 |

Manufacturing Procedure:

10. 1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

c) Micro suspension

15. 1. Weigh 4.0 g glass beads in custom made tube GL 25, 4 cm (the beads fill half of the tube).
2. Add 50 mg compound, disperse with spatulum and vortex.
3. Add 2 ml gelatin solution (weight beads: gelatin solution = 2:1) and vortex.
4. Cap and wrap in aluminum foil for light protection.
20. 5. Prepare a counter balance for the mill.
6. Mill for 4 hours, 20/s in a Retsch mill (for some substances up to 24 hours at 30/s).
7. Extract suspension from beads with two layers of filter (100 µm) on a filter holder, coupled to a recipient vial by centrifugation at 400 g for 2 min.
25. 8. Move extract to measuring cylinder.

- 44 -

9. Repeat washing with small volumes(here 1 ml steps) until final volume is reached or extract is clear.
10. Fill up to final volume with gelatin and homogenize.

5 The following examples and references are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

Examples

10

A: starting materials

Preparation of 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one

i) 1-Ethyl-3,3-dimethyl-6-nitro-1,3-dihydro-indol-2-one

15 A solution of 3,3-dimethyl-6-nitro-1,3-dihydro-indol-2-one (6g, 29.10 mmol) in anhydrous *N,N*-dimethylformamide (DMF) (35 ml) was treated with sodium hydride. The resulting suspension was stirred for 1 h at 60°C. A solution of bromoethane (2.17 mL, 3.17 g, 29.10 mmol) in DMF (10 ml) was added. The mixture was allowed to cool to room temperature and stirred for 1 h. After removal of the solvent the mixture was quenched with water (100 ml) and extracted with ethyl acetate (3 x 100 ml). The extract was dried over Na₂SO₄, evaporated and the crude product was purified by column chromatography on silica gel. Elution with ethyl acetate/*n*-heptane (1:3) yielded 5.94 g (87%) of a yellow solid.

20

MS: M = 235.3 (ESI+)

25 ¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.16 (t, 3H), 1.32 (s, 6 H), 3.81 (q, 2H), 7.66 (d, 1H), 7.86 (s, 1H), 7.97 (d, 1H)

ii) 6-Amino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one

To a solution of 1-ethyl-3,3-dimethyl-6-nitro-1,3-dihydro-indol-2-one (5.9 g, 25.19 mmol) in methanol/tetrahydrofuran (THF) (1:1, 80 ml) palladium on charcoal (10

- 45 -

%, 1.2 g) was added and the mixture hydrogenated at room temperature for 4 h. After filtration and evaporation of the solvents 5.05 g (98%) 6-amino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one was isolated as white solid.

MS: M = 205.0 (API+)

5 ¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.11 (t, 3H), 1.17 (s, 6H), 3.58 (q, 2H), 5.12 (br, 2H), 6.21 (d, 1H), 6.25 (s, 1H), 6.92 (d, 1H)

iii) *N*-(1-Ethyl-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-yl)-acetamide

10 A solution of 6-amino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one (5.05 g, 24.72 mmol) in acetic anhydride (80 ml) was stirred at room temperature for 4 h. The mixture was poured onto ice water (150 ml), allowed to warm to room temperature and was stirred again for 2 h. After extraction with ethyl acetate (3 x 100 ml), the combined organic layers were washed with sat. NaHCO₃-solution (3 x 100 ml), brine (100 ml) and dried over sodium sulfate. After removal of the solvent the crude product was purified by column chromatography on silica gel (ethyl acetate/*n*-heptane 1:1) yielding 5.6 g (91 %) *N*-(1-ethyl-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-yl)-acetamide as light yellow solid.

15 MS: M = 247.1 (API+)

19 ¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.13 (t, 3H), 1.23 (s, 6H), 2.04 (s, 3H), 3.63 (q, 2H), 7.12 (d, 1 H), 7.23 (d, 1H), 7.37 (s, 1H), 9.97 (br, 1H)

20 iv) *N*-(1-ethyl-3,3-dimethyl-5-nitro-2-oxo-2,3-dihydro-1H-indol-6-yl)-acetamide

25 To a solution of *N*-(1-ethyl-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-yl)-acetamide (5.6 g, 22.73 mmol) in acetic anhydride (70 ml) nitric acid (100 %, 1.96 g, 1.29 ml, 31.2 mmol) was added at 0 °C. The mixture was stirred for 30 min, then poured onto ice water (150 ml). After stirring for 4 h the mixture was extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with sodium hydroxide solution (1M, 100 ml) and water (100 ml), dried over sodium sulfate and concentrated. The crude product was purified by column chromatography on silica gel (ethyl acetate/*n*-heptane 1:1) to yield 5.2 g (78 %) *N*-

- 46 -

(1-ethyl-3,3-dimethyl-5-nitro-2-oxo-2,3-dihydro-1H-indol-6-yl)-acetamide as a yellow solid.

MS: M = 292.0 (API+)

5 ¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.16 (t, 3H), 1.31 (s, 6H), 2.13 (s, 3H), 3.71 (m, 2H), 7.54 (s, 1H), 8.12 (s, 1H), 10.39 (br, 1H)

v) 6-Amino-1-ethyl-3,3-dimethyl-5-nitro-1,3-dihydro-indol-2-one

10 *N*-(1-ethyl-3,3-dimethyl-5-nitro-2-oxo-2,3-dihydro-1H-indol-6-yl)-acetamide (5.2 g, 17.85 mmol) was dissolved in ethanol (40 ml). After addition of hydrochloric acid (25 %, 8 ml, 81.44 mmol) the mixture was stirred under reflux for 3 h. The reaction mixture was allowed to cool down to room temperature and then quenched with water (80 ml). The yellow precipitate was isolated by suction and washed with ethanol/water (1:1). The solid was dissolved in ethyl acetate, dried over sodium sulfate and concentrated to yield 4.15 g (93 %) 6-amino-1-ethyl-3,3-dimethyl-5-nitro-1,3-dihydro-indol-2-one as a orange solid.

15 MS: M = 250.0 (API+)

¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.15 (t, 3H), 1.27 (s, 6H), 3.64 (m, 2H), 6.54 (s, 1H), 7.67 (br, 2H), 7.95 (s, 1H)

vi) 5,6-Diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one

20 To a solution of 6-amino-1-ethyl-3,3-dimethyl-5-nitro-1,3-dihydro-indol-2-one (4.15 g, 16.65 mmol) in ethanol (80 ml) PtO₂ (0.4 g) was added and the mixture hydrogenated at room temperature for 3.5 h. After filtration and evaporation of the solvents 3.25 g (89 %) 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one was isolated as orange solid.

MS: M = 220.0 (API+)

25 ¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.10 (t, 3H), 1.13 (s, 6H), 3.53 (m, 2H), 4.08 (br, 2H), 4.48 (br, 2H), 6.27 (s, 1H), 6.50 (s, 1H)

- 47 -

Preparation of 5,6-diamino-1,3,3-trimethyl-1,3-dihydro-indol-2-one

5,6-diamino-1,3,3-trimethyl-1,3-dihydro-indol-2-one was prepared in an analogous 6-step-synthesis as described for 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one.

5 MS: M = 206.1 (API+)

¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.57 (s, 6H), 3.43 (s, 3H), 4.94 (br, 4H), 6.66 (s, 1H), 6.95 (s, 1H)

Preparation of 5,6-diamino-3,3-dimethyl-1-propyl-1,3-dihydro-indol-2-one

10 5,6-diamino-3,3-dimethyl-1-propyl-1,3-dihydro-indol-2-one was prepared in an analogous 6-step-synthesis as described for 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one.

MS: M = 234.1 (API+)

¹H-NMR (400 MHz, DMSO): δ (ppm) = 0.82 (t, 3H), 1.15 (s, 6H), 1.58 (m, 2H), 3.46 (q, 2H), 4.16 (br, 2H), 4.45 (br, 2H), 6.27 (s, 1H), 6.50 (s, 1H)

15 Preparation of 5,6-diamino-1-isopropyl-3,3-dimethyl-1,3-dihydro-indol-2-one

5,6-diamino-3,3-dimethyl-1-isopropyl-1,3-dihydro-indol-2-one was prepared in an analogous 6-step-synthesis as described for 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one.

MS: M = 234.1 (API+)

20 ¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.12 (s, 6H), 1.33 (d, 6H), 4.09 (br, 2H), 4.40 (m, 1H), 4.46 (br, 2H), 6.46 (s, 1H), 6.48 (s, 1H)

Preparation of 5-trifluoromethyl-2H-pyrazole-3-carboxylic acid

i) 1-Benzyl-5-furan-2-yl-3-trifluoromethyl-1H-pyrazole

To a solution of 50g (0.240mol) 4,4,4-trifluoro-1-(2-furyl)-1,3-butanedione in 24ml (0.024mol) 1M solution of hydrogen chloride in ethanol and further 520ml EtOH was added 50g (0.248mol) benzylhydrazine dihydrochloride in small portion at room temperature. The reaction mixture was then heated under reflux for 7h. After cooling to room temperature the reaction mixture was neutralized with saturated NaHCO_3 , the EtOH was distilled off and the residual oil/water mixture was extracted with 300ml dichloromethane. The organic phase was washed twice with 100 ml water and dried over Na_2SO_4 and concentrated in vacuo to give 73.7g 1-benzyl-5-furan-2-yl-3-trifluoromethyl-1H-pyrazole as a brown oil which was used crude for the next reaction. MS: M = 293.0 (API+)

ii) 2-Benzyl-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid

To a solution of 9.5g (0.0325mol) 1-benzyl-5-furan-2-yl-3-trifluoromethyl-1H-pyrazole in 350mL acetone was added 27.2g (0.172mol) potassium permanganate in 450ml water. The reaction mixture was heated at 60°C for 4h. After cooling to room temperature 200ml 2-propanol were added and the mixture was stirred over night, it was filtered through a Celite pad and washed with 1l acetone. The filtrate was concentrated in vacuo down to 150mL. The residue was dissolved in 20mL 2M NaOH and 150mL water. The resulting aqueous phase was washed twice with 70ml ethyl ether and was then acidified with 30ml 5M HCl solution. The suspension was extracted with 200 and 50ml ethyl acetate (EtOAc). The combined organic extracts were washed with 30mL water and 5mL brine and concentrated. The residue was purified by silica gel chromatography (CH_2Cl_2 with 1% acetic acid) to give 6.1g (0.022mol, 67%) of 2-benzyl-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid as a off-white solid. MS: M = 271.1 (ESI+)

iii) 5-Trifluoromethyl-2H-pyrazole-3-carboxylic acid

About 50ml ammonia were condensed into a three-neck-flask in an ethanol-dry ice bath and 100mg (3.70mmol) 2-benzyl-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid were added. To the solution sodium was added in small portions until the blue

- 49 -

color stayed for more then 5 minutes (about 260mg, 11.3mmol). The ammonia was evaporated overnight. Water was added and acidified with 2N HCl solution. The aqueous phase was extracted twice with ethyl acetate, the combined organic phases were dried over Na_2SO_4 , the solvent was evaporated in vacuo to give 560mg (3.11mmol, 84%) 5-trifluoromethyl-2H-pyrazole-3-carboxylic acid as a yellow solid that was used without further purification. MS: M = 179.0 (API-)

5-Methoxy-1H-pyrazole-3-carboxylic acid ethyl ester

5-Hydroxy-1H-pyrazole-3-carboxylic acid ethyl ester (300 mg, 1.92 mmol) was dissolved in anhydrous *N,N*-dimethylformamide (DMF) (35 ml) and cesium carbonate (626 mg, 1.92 mmol) was added. The resulting suspension was treated with iodomethane (120 μl , 273 mg, 1.92 mmol) and stirred for 12 h at room temperature. The reaction mixture was quenched with saturated potassium hydrogen sulfate solution and extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with water (50 ml) and brine (50 ml). The extract was dried over sodium sulfate, evaporated and the crude product was purified by column chromatography on silica gel. Elution with ethyl acetate/*n*-heptane (1:3) yielded 124 mg (38%) of a white solid.

MS: M = 171.2 (ESI+)

$^1\text{H-NMR}$ (400 MHz, DMSO): δ (ppm) = 1.29 (t, 3H), 3.79 (s, 3H), 4.29 (q, 2H), 6.21 (s, 1H), 13.10 (br, 1H)

5-Methoxy-1H-pyrazole-3-carboxylic acid

5-Methoxy-1H-pyrazole-3-carboxylic acid ethyl ester (120 mg, 0.71 mmol) was dissolved in tetrahydrofuran (THF) (2 mL). After addition of sodium hydroxide (2M in water, 1 mL) the mixture was stirred under reflux for 2 h. The reaction mixture was cooled to room temperature and acidified (pH 3) by addition of hydrochloric acid and extracted with ethyl acetate (3 x 20 ml). The extract was dried over sodium sulfate and evaporated to yield 86 mg (86 %) of a white solid.

- 50 -

Preparation of 2-(3,3-Bis-methylsulfanyl-acryloyl)-5-ethyl-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one

(i) 5-Ethyl-2-(1-hydroxy-ethyl)-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one

5 A mixture of 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one (10 g, 46 mmol), 2-hydroxy-propionic acid (9.13 g, 91.2 mmol) in HCl (100 mL, 4N) was refluxed for 16h. After cooling, neutralization with aqueous ammonia (25 %) and stirring for 1.5 h the precipitate was filtered and dried in vacuo at 50 °C yielding 12.29 g (95 %) of a grey solid.

10 MS: M = 274.3 (ESI+)

¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.17 (t, 3H), 1.28 (s, 6H), 1.48 (d, 3H), 3.73 (q, 2H), 4.90 (m, 1H), 5.68 (d, 1H, OH), 7.05 (s, 1H), 7.43 (s, 1H), 12.2 (br, 1H)

(ii) 2-Acetyl-5-ethyl-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one

15 5-Ethyl-2-(1-hydroxy-ethyl)-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one (13 g, 47.6 mmol) and manganese(IV)dioxide (16.54 g, 190 mmol) were suspended in chloroform (400 mL) and stirred at 65 °C for 16 h. The mixture was cooled, filtered over Celite and the filtrate concentrated in vacuo yielding 11.6 g (90%) of a beige solid.

20 MS: M = 272.0 (ESI+)

¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.18 (t, 3H), 1.32 (s, 6H), 2.66 (s, 3H), 3.77 (q, 2H), 7.00 and 7.40 (s, 1H, two tautomeric forms), 7.50 and 7.80 (s, 1H, two tautomeric forms), 13.3 (br, 1H)

- 51 -

(iii) 2-Acetyl-5-ethyl-7,7-dimethyl-1-(tetrahydro-pyran-2-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one

2-Acetyl-5-ethyl-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one (11.7 g, 43.1 mmol) and p-toluenesulfonic acid monohydrate (0.82 g, 4.3 mmol) were dissolved in dichloromethane (200 mL). To this solution 3,4-dihydro-2H-pyran (4.81 g, 56 mmol) was added and the mixture stirred at reflux for 24 h. The mixture was filtered, the filtrate washed with water (2 x 100mL), dried over sodium sulfate and concentrated in vacuo. The crude product was purified by column chromatography on silica (dichloromethane/methanol 93:3) yielding 6.8 g (44 %) of a light yellow solid.

MS: M = 356.3 (ESI+)

¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.21 (t, 3H), 1.32 (s, 6H), 1.59 – 2.23 (m, 6H), 2.70 (s, 3H), 3.65 (t, 1H), 3.80 (m, 2H), 4.15 (d, 1H), 6.47 (d, 1H), 7.30 (s, 1H), 7.82 (s, 1H)

15 (iv) 2-(3,3-Bis-methylsulfanyl-acryloyl)-5-ethyl-7,7-dimethyl-1-(tetrahydro-pyran-2-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one

To a suspension of sodium hydride (0.57 g, 22.5 mmol) in toluene (20 mL) at 80 °C *tert*-butanol (0.88 g, 11.8 mmol) was added and the mixture stirred for 2h. After cooling to room temperature a suspension of 2-acetyl-5-ethyl-7,7-dimethyl-1-(tetrahydro-pyran-2-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one (2g, 5.63 mmol) and carbon disulfide (0.43 g, 5.63 mmol) in *N,N*-dimethylformamide (DMF) (12 mL) was added in small portions, the mixture stirred for 30 min at room temperature and finally stirred for 30min at 80 °C. After cooling to room temperature, water (20 mL) and ethyl acetate (15 mL) were added, the layers separated and the aqueous layer extracted with ethyl acetate (3 x 10 mL). The combined organic phases were washed with water (3 x 10 mL) and concentrated in vacuo to yield 2.27 g (88%) of 2-(3,3-bis-methylsulfanyl-acryloyl)-5-ethyl-7,7-dimethyl-1-(tetrahydro-pyran-2-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one which was partially deprotected in the course of the reaction. It was used without any further purification in the next step.

- 52 -

MS: M = 460.1 (ESI+)

(v) 2-(3,3-Bis-methylsulfanyl-acryloyl)-5-ethyl-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one

Crude 2-(3,3-bis-methylsulfanyl-acryloyl)-5-ethyl-7,7-dimethyl-1-(tetrahydro-5 pyran-2-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one (2.25 g, 4.9 mmol) and *p*-toluenesulfonic acid monohydrate (0.5 g, 2.6 mmol) was dissolved in methanol (25 mL) and water (3 mL) and stirred at reflux for 3 h. After cooling to room temperature, water (50 mL) was added and the mixture extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with water and concentrated in vacuo. The crude product was recrystallized from methanol to yield 10 2-(3,3-bis-methylsulfanyl-acryloyl)-5-ethyl-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one (0.71 g, 39 %) as yellow solid.

MS: M = 376.3 (ESI+)

¹H-NMR (400 MHz, CDCl₃): δ (ppm) = 1.31 (t, 3H), 1.42 (s, 6H), 2.63 (s, 3H), 15 2.72 (s, 3H), 3.83 (m, 2H), 7.13 and 7.25 (s, 1H, two tautomeric forms), 7.49 (s, 1H), 7.58 and 7.65 (s, 1H, two tautomeric forms), 11.5 (br, 1H)

B: Final Products

Examples 1 to 43

Standard Procedure:

20 Preparation of 1-Isopropyl-6-(5-methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one (Example 11)

5-Methyl-1H-pyrazole-3-carboxylic acid (126 mg, 1 mmol) and 5,6-diamino-1-isopropyl-1,3-dihydro-benzoimidazol-2-one (206 mg, 1 mmol) were heated to 160 °C in a mixture of polyphosphoric acid (5 g) and phosphorus pentoxide (500 mg, 25 3.5 mmol) for 6 h. This mixture was poured on water (20 ml) and stirring continued until a precipitate formed. After filtration the crude product was suspended in water and neutralized by the addition of aqueous ammonia (25 %).

- 53 -


The precipitate was collected, washed with water and dried in *vacuo*. Purification was achieved by chromatography on silica (dichloromethane/methanol 95:5) yielding 1-isopropyl-6-(5-methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one as slightly yellow solid. Yield 36 mg (12 %)

5 Using the experimental conditions reported above and the appropriate starting materials, the following derivatives 1 to 43 were prepared:

| Example No. | Systematic Name | MS (Method) | ¹ H-NMR |
|-------------|--|----------------|--------------------|
| 1 | 7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-3,5,6,7-tetrahydro-imidazo[4,5-f]indole | 268.3(ESI+) | |
| 2 | 1-[7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-6,7-dihydro-3H-imidazo[4,5-f]indol-5-yl]-ethanone | 310.3 (ESI+) | |
| 3 | 8,8-Dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one | 296.3 (ESI+) | |
| 4 | 2-(5-Isobutyl-2H-pyrazol-3-yl)-8,8-dimethyl-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one | 338.0 (API+) | |

- 54 -

| Example No. | Systematic Name | MS (Method) | ¹ H-NMR |
|-------------|--|-----------------|--|
| 5 | 7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 282.2 (ESI+) | [D6]DMSO, 400 MHz: 1.30 (d, 6H), 2.32 (s, 3H), 6.54 and 6.56 (s, 1H, two tautomeric forms), 6.89 and 7.00 (s, 1H, two tautomeric forms), 7.30 and 7.48 (s, 1H, two tautomeric forms), 10.18 and 10.23 (br, 1H, two tautomeric forms), 12.39 and 12.53 (br, 1H, two tautomeric forms), 12.85 and 12.89 (br, 1H, two tautomeric forms) |
| 6 | 2-(5-Isobutyl-2H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one | 324.0 (API+) | |
| 7 | 2-(5-Methyl-2H-Pyrazol-3-yl)-spiro[7,7-cyclopentan-5,7-dihydro-3H-imidazo[4,5-f]indol-6]-one; or according to the actual IUPAC-nomenclature: 2-(5-Methyl-2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one | 308.3 (ESI+) | |



| Example No. | Systematic Name | MS (Method) | ¹ H-NMR | |
|-------------|---|---|---|--|
| |  8 | 2-(5-Isobutyl-2H-pyrazol-3-yl)-spiro[7,7-cyclopentan-5,7-dihydro-1H-imidazo[4,5-f]indol-6]-one; or according to the actual IUPAC-nomenclature: 2-(5-Isobutyl-2H-pyrazol-3-yl)-spiro[5,7-dihydro[cyclopentan-1',7-imidazo[4,5-f]indol]-6(3H)-one | 350.1 (API+) | |
| 9 | 6-(5-Methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one | 255 (API+) | [D6]DMSO, 400 MHz: 2.30 (s, 3H), 6.53 (s, 1H), 7.00 (s, 2H), 10.42 (br, 2H), 12.38 (br, 1H), 12.86 (br, 1H) | |
| 10 | 3-Methyl-6-(5-methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one | 269.1 (API+) | [D6]DMSO, 400 MHz: 2.30 (s, 3H), 3.36 (s, 3H), 6.54 (s, 1H), 7.05 (s, 1H), 7.13 (s, 1H), 10.65 (br, 1H), 12.50 (br, 1H), 12.86 (br, 1H) | |
| 11 | 3-Isopropyl-6-(5-methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one | 297.2 (API+) | [D6]DMSO, 400 MHz: 1.47 (d, 6H), 2.31 (s, 3H), 4.61 (m, 1H), 6.53 (s, 1H), 6.98 (s, 1H), 7.12 (d, 1H), 7.39 (s, 1H), 10.61 (br, 1H) | |

| Example No. | Systematic Name | MS (Method) | ¹ H-NMR |
|-------------|--|-----------------|---|
| 12 | 5-Ethyl-7,7-dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 310.1 (API+) | [D6]DMSO, 400 MHz: 1.17 (t, 3H), 1.31 (d, 6H), 2.31 (s, 3H), 3.75 (q, 2H), 6.58 (s, 1H), 6.95 and 7.22 (s, 1H, two tautomeric forms), 7.39 and 7.55 (s, 1H, two tautomeric forms), 12.60 (br, 1H), 12.90 (br, 1H) |
| 13 | 5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 338.1 (API+) | [D6]DMSO, 400 MHz: d = 12.64 (bs, 1H), 7.48 (s, 1H), 7.09 (s, 1H), 6.59 (s, 1H), 3.76 (q, 2H), 2.64 (t, 2H), 1.72 - 1.63 (m, 2H), 1.31 (s, 6H), 1.19 (t, 3H), 0.95 (t, 3H) |
| 14 | 5,7,7-Trimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 324.1 (API+) | |
| 15 | 5-Ethyl-2-(5-isobutyl-2H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 352.1 (API+) | |
| 16 | 2-(5-Isobutyl-2H-pyrazol-3-yl)-5,7,7-trimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 338.1 (API+) | |

- 57 -

| Example No. | Systematic Name | MS (Method) | ¹ H-NMR |
|-------------|---|-----------------|--------------------|
| 17 | 2-(4,5-Dimethyl-1 <i>H</i> -pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1 <i>H</i> -imidazo[4,5- <i>f</i>]indol-6-one | 294.0 (API-) | |
| 18 | 7,7-Dimethyl-2-[5-(3-methyl-butyl)-1 <i>H</i> -pyrazol-3-yl]-5,7-dihydro-1 <i>H</i> -imidazo[4,5- <i>f</i>]indol-6-one | 336.1 (API-) | |
| 19 | 2-(5-Ethyl-4-methyl-1 <i>H</i> -pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1 <i>H</i> -imidazo[4,5- <i>f</i>]indol-6-one | 308.1 (API-) | |
| 20 | 7,7-Dimethyl-2-(1 <i>H</i> -pyrazol-3-yl)-5,7-dihydro-1 <i>H</i> -imidazo[4,5- <i>f</i>]indol-6-one | 268,0 (ESI+) | |
| 21 | 2-(5-Cyclopropyl-1 <i>H</i> -pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1 <i>H</i> -imidazo[4,5- <i>f</i>]indol-6-one | 308,1 (ESI+) | |
| 22 | 2-(5-Isopropyl-2 <i>H</i> -pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1 <i>H</i> -imidazo[4,5- <i>f</i>]indol-6-one | 310,1 (ESI+) | |

- 58 -

| Example No. | Systematic Name | MS (Method) | ¹ H-NMR |
|-------------|---|-----------------|--------------------|
| 23 | 8,8-Dimethyl-2-(5-propyl-2 <i>H</i> -pyrazol-3-yl)-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one | 324,2 (ESI+) | |
| 24 | 8,8-Dimethyl-2-(1 <i>H</i> -pyrazol-3-yl)-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one | 282,2 (ESI+) | |
| 25 | 2-(5-Cyclopropyl-1 <i>H</i> -pyrazol-3-yl)-8,8-dimethyl-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one | 322,2 (ESI+) | |
| 26 | 2-(5-Isopropyl-2 <i>H</i> -pyrazol-3-yl)-8,8-dimethyl-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one | 324,2 (ESI+) | |
| 27 |  | 294,2 (ESI+) | |
| 28 |  | 336,2 (ESI+) | |


- 59 -

| Example No. | Systematic Name | MS (Method) | ¹ H-NMR |
|-------------|---|-----------------|--|
| 29 | 2-(5-Propyl-2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one | 336,2 (ESI+) | |
| 30 | 5,7,7-Trimethyl-2-(1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 282,2 (ESI+) | |
| 31 | 5,7,7-Trimethyl-2-(5-methyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 296,0 (API+) | [D6]DMSO, 400 MHz: d = 12.89 (m, 1H), 12.61 (m, 1H), 7.56-6.94 (m, 2H), 6.55 (s, 1H), 3.19 (s, 3H), 2.32 (s, 3H), 1.31 (s, 6H) |
| 32 | 5-Ethyl-7,7-dimethyl-2-(1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 296,2 (ESI+) | |
| 33 | 5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one; compound with acetic acid | 338,2 (ESI+) | |
| 34 | 5-Isopropyl-7,7-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one | 324,1 (API+) | [D6]DMSO, 400 MHz: 1.28 (s, 6H), 1.45 (d, 3H), 2.31 (s, 3H), 4.56 (br, 1H), 6.55 (s, 1H), 6.88 and 7.09 and 7.32 and 7.54 (2H, two tautomeric forms), 12.61 (NH), 12.87 (NH) |

- 60 -

| Example No. | Systematic Name | MS (Method) | ¹ H-NMR |
|-------------|--|-----------------|---|
| 35 | 5-Isopropyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one | 352,2 (API+) | [D6]DMSO, 400 MHz: 0.95 (t, 3H), 1.29 (s, 6H), 1.44 (d, 6H), 1.66 (m, 2H), 2.64 (t, 2H), 4.56 (br, 1H), 6.57 (s, 1H), 7.71 and 7.31 (1H, two tautomeric forms), 7.35 and 7.55 (1H, two tautomeric forms), 12.49 and 12.60 (NH, two tautomeric forms), 12.90 (NH) |
| 36 | 7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5-propyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one | 324,1 (API+) | [D6]DMSO, 400 MHz: 0.88 (t, 3H), 1.31 (s, 6H), 1.66 (m, 2H), 2.31 (s, 3H), 3.69 (t, 2H), 6.55 (s, 1H), 6.95 and 7.22 (1H, two tautomeric forms), 7.35 and 7.56 (1H, two tautomeric forms), 12.54 and 12.62 (NH, two tautomeric forms), 12.88 (NH) |
| 37 | 7,7-Dimethyl-5-propyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 352.1 (API+) | [D6]DMSO, 400 MHz: 0.88 (t, 3H), 0.95 (t, 3H), 1.31 (s, 6H), 1.67 (m, 4H), 2.64 (t, 2H), 3.69 (t, 2H), 6.58 (s, 1H), 6.95 and 7.23 (s, 1H, two tautomeric forms), 7.39 and 7.57 (s, 1H, two tautomeric forms), 12.60 (br, 1H), 12.91 (br, 1H) |

| Example No. | Systematic Name | MS (Method) | ¹ H-NMR |
|-------------|---|-----------------|---|
| 38 | 7,7-Dimethyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one | 336.0 (API+) | [D6]DMSO, 400 MHz: 1.32 (s, 6H), 6.94 and 7.04 (1H, two tautomeric forms), 7.22 and 7.51 (1H, two tautomeric forms), 7.28 and 7.60 (1H, two tautomeric forms), 10.35 (NH), 12.88 and 12.98 (NH, two tautomeric forms), 14.64 (NH) |
| 39 | 5-Ethyl-7,7-dimethyl-2-(5-trifluoromethyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 364.1 (API+) | [D6]DMSO, 400 MHz: 1.18 (t, 3H), 1.32 (d, 6H), 3.79 (q, 2H), 7.20 (s, 1H), 7.28 (s, 1H), 7.63 (s, 1H), |
| 40 | 5-Isopropyl-7,7-dimethyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one | 378.0 (API+) | [D6]DMSO, 400 MHz: 1.18 (s, 6H), 1.46 (d, 6H), 4.58 (m, 1H), 7.23 (br,1H), 7.28 (s, 1H), 7.62 (br,1H), 12.99 (NH), 14.67 (NH) |
| 41 | 7,7-Dimethyl-5-propyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one | 378.0 (API+) | [D6]DMSO, 400 MHz: 0.88 (t, 3H), 1.34 (s, 6H), 1.67 (m, 2H), 3.74 (t, 2H), 7.18 (br, 1H), 7.28 (s, 1H), 7.63 (br,1H), 13.02 (NH), 14.64 (NH) |
| 42 | 5,7,7-Trimethyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one | 350.0 (API+) | [D6]DMSO, 400 MHz: d = 14.66 (s, 1H), 13.04 (s, 1H), 7.63 (m, 1H), 7.29 (m, 1H), 7.15 (m, 1H), 3.22 (s, 3H), 1.34 (s, 6H) |

| Example No. | Systematic Name | MS (Method) | ¹ H-NMR |
|---|--|----------------|--------------------|
| 43  | 2-(5-Cyclopropyl-2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one 334.2 (ESI+) | | |

Example 44:

5-Ethyl-2-(5-methoxy-1H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one

5 5-Methoxy-1H-pyrazole-3-carboxylic acid (86 mg, 0.61 mmol), 1-hydroxybenzotriazole hydrate (111 mg, 0.73 mmol) and triethylamine (253 μ l, 184 mg, 1.82 mmol) were dissolved in *N,N*-dimethylformamide (DMF) (2 ml) and after the addition of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (139 mg, 0.73 mmol) dissolved in DMF (2 ml) the reaction mixture was stirred at room temperature. After 1 hour a solution of 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one in DMF (2 ml) was added and the reaction mixture was stirred at room temperature for 16 hours. The solvent was removed under reduced pressure, the residue was quenched with water (20 ml) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine (15 ml), dried over sodium sulfate and evaporated. The residue was dissolved in ethanol (5 ml) and after the addition of hydrochloric acid (10 M, 2 ml) it was stirred under reflux for 2 hours. The ethanol was evaporated and the residue was adjusted to pH 9-10 with ammonium hydroxide. After the addition of water (20 ml) the aqueous phase was extracted with ethyl acetate (3 x 20 ml). The combined organic layers were washed with brine (10 ml), dried over sodium sulfate and evaporated. The crude product was purified by column chromatography on silica gel. Elution with ethyl acetate/*n*-heptane (9:1) yielded 56 mg (28%) of an off-white solid.

MS: M = 326.1 (API+)

- 63 -

¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.19 (t, 3H), 1.32 (s, 6H), 3.76 (q, 2H), 3.84 (s, 3H), 6.28 (s, 1H), 7.14 (s, 1H), 7.56 (s, 1H), 12.80 (br, 2H)

Example 45:

5 5-Ethyl-7,7-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one

Hydrazine monohydrate (0.92 g, 1.8 mmol) was added to a suspension of 2-(3,3-bis-methylsulfanyl-acryloyl)-5-ethyl-7,7-dimethyl-1-(tetrahydro-pyran-2-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one (0.68 g, 1.81 mmol) in acetonitrile (15 mL) and stirred for 24 h. After cooling to room temperature the precipitate was
10 collected, washed with acetonitrile and ether to yield 0.5 g (81 %) of a pale white powder.

MS: M = 342.1 (API+)

15 ¹H-NMR (400 MHz, DMSO): δ (ppm) = 1.19 (t, 3H), 1.31 (s, 6H), 2.53 (s, 3H), 3.76 (m, 2H), 6.83 (s, 1H), 6.95 – 7.65 (br m, 2H, tautomeric forms), 12.75 (br, 1H), 13.45 (br, 1H)

List of References

Adams, R.R., et al., *Trends Cell Biol.* 11 (2001) 49-54

Bastin, R.J., et al., *Organic Proc. Res. Dev.* 4 (2000) 427-435

Bischoff, J.R., and Plowman, G.D., *Trends Cell Biol.* 9 (1999) 454-459

5 DE 34 17 643

DE 36 42 315

DE 37 01 277

Djuric, S.W., et al., *J. Med. Chem.* 43 (2000) 2975-2981

EP 0 189 103

10 EP 0 318 902

EP 0 868 519

EP 1 051 500

Giet, R., and Prigent, C., *J. Cell Sci.* 112 (1999) 3591-3601

Harrington, E.A., et al., *Nat. Med.* 10 (2004) 262-267

15 Hunter, T., *Cell* 50 (1987) 823-829

Isola, J.J., et al., *Am. J. Pathology* 147 (1995) 905-911

Jia, Z.J., et al., *Bioorg. Med. Chem. Lett.* 12 (2002) 1651-1655

Mahata, P.K., et al., *Tetrahedron* 59 (2003) 2631-2639

Martins, M.A.P., et al., *Synthesis* 15 (2003) 2353-2357

20 Mertens, A., et al., *J. Med. Chem.* 30 (1987) 1279-1287

Nigg, E.A., *Nat. Rev. Mol. Cell Biol.* 2 (2001) 21-32

Ochi, H., et al., *Chem. Pharm. Bull.* 31 (1983) 1228-1234

Pruitt, J.R., et al., *J. Med. Chem.* 46 (2003) 5298-5315

Sen, S., et al., *J. Natl. Cancer Inst.* 94 (2002) 1320-1329

25 Sewald, N., et al., *Liebigs Ann. Chem.* (1992) 947-952

Stahl, P.H., and Wermuth, G., (editors), *Handbook of Pharmaceutical Salts*, Verlag Helvetica Chimica Acta (VHCA), Zürich (2002)

Stanovnik, B., and Svetec, J., *Science of Synthesis* 12 (2002) 15-225

Subramanyam, C., *Synth. Commun.* 25 (1995) 761-774

30 US 4,835,280A

US 4,954,498

US 5,212,186A

US 6,207,401

van Herk, T., et al., *J. Med. Chem.* 46 (2003) 3945-3951

35 von der Saal, W., et al., *J. Med. Chem.* 32 (1989) 1481-1491

- 65 -

WO 00/44728
WO 00/47212
WO 01/21594
WO 01/21595
5 WO 01/21596
WO 01/21597
WO 01/55116
WO 01/77085
WO 02/057259
10 WO 02/059111
WO 02/059112
WO 02/062789
WO 02/066461
WO 02/068415
15 WO 02/22601
WO 02/22602
WO 02/22603
WO 02/22604
WO 02/22605
20 WO 02/22606
WO 02/22607
WO 02/22608
WO 02/50065
WO 02/50066
25 WO 02/96905
WO 03/035065
WO 03/077921
WO 03/078423
WO 03/078426
30 WO 03/078427
WO 04/000833
WO 04/005283
WO 04/032928
WO 95/19169

- 66 -


WO 95/23141

WO 97/42187

WO 99/06396

Patent Claims

1. Use of a compound of formula I



formula I,

5 wherein

R¹ is hydrogen, alkyl, or -C(O)-alkyl;
 R² is hydrogen, alkyl, cyano or halogen;
 R³ is hydrogen, alkyl, (C₃-C₆)-cycloalkyl, alkoxy or alkylsulfanyl;
 X is -C(O)- or -CH₂-;
 10 Y is -NH-, -CH₂-CR⁴R⁵-, -CR⁴R⁵-CH₂- or -CR⁴R⁵-; wherein
 R⁴ is hydrogen or alkyl; and
 R⁵ is hydrogen or alkyl,
 or alternatively
 R⁴ and R⁵ form together with the carbon atom to which they
 15 are attached a cycloalkyl ring;

and all pharmaceutically acceptable salts thereof;

for the manufacture of a medicament for the treatment of cancer.

2. Use of the compounds according to formula I in claim 1, wherein
 20 R³ is hydrogen, alkyl, (C₃-C₆)-cycloalkyl,
 for the manufacture of a medicament for the treatment of cancer.

3. Use of the compounds according to formula I in claim 1 or 2, wherein
 X is -CH₂-;
 for the manufacture of a medicament for the treatment of cancer.

4. Use of the compounds according to formula I in claim 1 or 2, wherein

X is -C(O)-;

for the manufacture of a medicament for the treatment of cancer.

5. Use of the compounds according to formula I in claim 1 selected from the

5 group consisting of

7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-3,5,6,7-tetrahydro-imidazo[4,5-f]indole;

10 1-[7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-6,7-dihydro-3H-imidazo[4,5-f]indol-5-yl]-ethanone;

8,8-Dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one;

2-(5-Isobutyl-2H-pyrazol-3-yl)-8,8-dimethyl-1,5,7,8-tetrahydro-imidazo[4,5-g]quinolin-6-one;

15 7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

2-(5-Isobutyl-2H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

20 2-(5-methyl-2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one;

2-(5-Isobutyl-2H-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-f]indol]-6(3H)-one;

6-(5-Methyl-1H-pyrazol-3-yl)-3,5-dihydro-1H-benzo[1,2-d;4,5-d']diimidazol-2-one;

25 2-(4,5-Dimethyl-1H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

7,7-Dimethyl-2-[5-(3-methyl-butyl)-1H-pyrazol-3-yl]-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

30 2-(5-Ethyl-4-methyl-1H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

- 69 -

7,7-Dimethyl-2-(1*H*-pyrazol-3-yl)-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

2-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

5 2-(5-Isopropyl-2*H*-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

8,8-Dimethyl-2-(5-propyl-2*H*-pyrazol-3-yl)-1,5,7,8-tetrahydro-imidazo[4,5-*g*]quinolin-6-one;

10 8,8-Dimethyl-2-(1*H*-pyrazol-3-yl)-1,5,7,8-tetrahydro-imidazo[4,5-*g*]quinolin-6-one;

2-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-8,8-dimethyl-1,5,7,8-tetrahydro-imidazo[4,5-*g*]quinolin-6-one

15 2-(5-Isopropyl-2*H*-pyrazol-3-yl)-8,8-dimethyl-1,5,7,8-tetrahydro-imidazo[4,5-*g*]quinolin-6-one;

2-(2*H*-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-*f*]indol]-6(3*H*)-one;

20 2-(5-Isopropyl-2*H*-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-*f*]indol]-6(3*H*)-one;

2-(5-Propyl-2*H*-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-*f*]indol]-6(3*H*)-one;

25 7,7-Dimethyl-2-(5-trifluoromethyl-2*H*-pyrazol-3-yl)-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

2-(5-Cyclopropyl-2*H*-pyrazol-3-yl)-spiro-5,7-dihydro[cyclopentane-1',7-imidazo[4,5-*f*]indol]-6(3*H*)-one;

30 3-Methyl-6-(5-methyl-1*H*-pyrazol-3-yl)-3,5-dihydro-1*H*-benzo[1,2-*d*;4,5-*d'*]diimidazol-2-one;

3-Isopropyl-6-(5-methyl-1*H*-pyrazol-3-yl)-3,5-dihydro-1*H*-benzo[1,2-*d*;4,5-*d'*]diimidazol-2-one;

5-Ethyl-7,7-dimethyl-2-(5-methyl-1*H*-pyrazol-3-yl)-5,7-dihydro-3*H*-imidazo[4,5-*f*]indol-6-one;

- 70 -

5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5,7,7-Trimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5 5-Ethyl-2-(5-isobutyl-2H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

2-(5-Isobutyl-2H-pyrazol-3-yl)-5,7,7-trimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

10 5,7,7-Trimethyl-2-(1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5,7,7-Trimethyl-2-(5-methyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-7,7-dimethyl-2-(1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

15 5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one; compound with acetic acid;

5-Isopropyl-7,7-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

5-Isopropyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

20 7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5-propyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

7,7-Dimethyl-5-propyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

25 5-Ethyl-7,7-dimethyl-2-(5-trifluoromethyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Isopropyl-7,7-dimethyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

7,7-Dimethyl-5-propyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

30 7,7-Dimethyl-5-propyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

- 71 -


5,7,7-Trimethyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-2-(5-methoxy-1H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one; and

5-Ethyl-7,7-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

for the manufacture of a medicament for the treatment of cancer.

6. A compound according to formula I,



10

formula I,

wherein

R¹ is alkyl or -C(O)-alkyl;

R² is hydrogen, alkyl, cyano or halogen;

15 R³ is hydrogen, alkyl, (C₃-C₆)-cycloalkyl, alkoxy or alkylsulfanyl;

X is -C(O)- or -CH₂-;

Y is -NH-, -CH₂-CR⁴R⁵-, -CR⁴R⁵-CH₂- or -CR⁴R⁵; wherein

R⁴ is hydrogen or alkyl; and

R⁵ is hydrogen or alkyl,

20 or alternatively

R⁴ and R⁵ form together with the carbon atom to which they are attached a cycloalkyl ring;

and all pharmaceutically acceptable salts thereof.

7. The compounds according to claim 6 selected from the group consisting of

5-Ethyl-7,7-dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5,7,7-Trimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-2-(5-isobutyl-2H-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

10 2-(5-Isobutyl-2H-pyrazol-3-yl)-5,7,7-trimethyl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5,7,7-Trimethyl-2-(1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

15 5,7,7-Trimethyl-2-(5-methyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Ethyl-7,7-dimethyl-2-(1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

20 5-Ethyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one; compound with acetic acid;

5-Isopropyl-7,7-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

25 5-Isopropyl-7,7-dimethyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

7,7-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-5-propyl-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

7,7-Dimethyl-5-propyl-2-(5-propyl-2H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

30 5-Ethyl-7,7-dimethyl-2-(5-trifluoromethyl-1H-pyrazol-3-yl)-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one;

5-Isopropyl-7,7-dimethyl-2-(5-trifluoromethyl-2H-pyrazol-3-yl)-5,7-dihydro-1H-imidazo[4,5-f]indol-6-one;

- 73 -

7,7-Dimethyl-5-propyl-2-(5-trifluoromethyl-2*H*-pyrazol-3-yl)-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

5,7,7-Trimethyl-2-(5-trifluoromethyl-2*H*-pyrazol-3-yl)-5,7-dihydro-3*H*-imidazo[4,5-*f*]indol-6-one;

5-Ethyl-2-(5-methoxy-1*H*-pyrazol-3-yl)-7,7-dimethyl-5,7-dihydro-3*H*-imidazo[4,5-*f*]indol-6-one;

5-Ethyl-7,7-dimethyl-2-(5-methylsulfanyl-1*H*-pyrazol-3-yl)-5,7-dihydro-1*H*-imidazo[4,5-*f*]indol-6-one;

3-Methyl-6-(5-methyl-1*H*-pyrazol-3-yl)-3,5-dihydro-1*H*-benzo[1,2-d;4,5-d']diimidazol-2-one;

3-Isopropyl-6-(5-methyl-1*H*-pyrazol-3-yl)-3,5-dihydro-1*H*-benzo[1,2-d;4,5-d']diimidazol-2-one; and

1-[7,7-Dimethyl-2-(5-methyl-2*H*-pyrazol-3-yl)-6,7-dihydro-3*H*-imidazo[4,5-*f*]indol-5-yl]-ethanone.

15 8. The compounds according to claim 6, wherein

R¹ is alkyl;

R² is hydrogen or alkyl;

X is -C(O)-; and

Y is -CR⁴R⁵-.

20 9. The compounds according to claim 6, wherein

R¹ is alkyl;

R² is hydrogen or alkyl;

R³ is hydrogen, alkyl or (C₃-C₆)-cycloalkyl;

X is -C(O)-; and

Y is -CR⁴R⁵-.


25 10. A process for the preparation of the compounds of formula I, wherein

R¹ is alkyl or -C(O)-alkyl;

30 by

a) reacting a compound of formula II

- 74 -




formula II,

wherein R¹ is alkyl or -C(O)-alkyl and X and Y have the significance given above for formula I;

5

with a compound of formula III,




formula III,

wherein A is -OH, -Cl, -H or -OMe and R² and R³ have the significance given above for formula I;

10

to give the compounds of formula I,



formula I,

15

wherein R¹ is alkyl or -C(O)-alkyl and R², R³, X and Y have the significance given above for formula I;

20

b) isolating said compound of formula I from the reaction mixture, and

if desired, converting it into a pharmaceutically acceptable salt.

25

11. A medicament containing one or more compounds according to anyone of claim 6 to 9 as active ingredients together with pharmaceutically acceptable adjuvants.

- 75 -

12. A medicament containing one or more compounds according to anyone of claim 6 to 9 as active ingredients together with pharmaceutically acceptable adjuvants for the treatment of cancer.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/010312

A. CLASSIFICATION OF SUBJECT MATTER

A61K31/4188 A61K31/4745 C07D487/04 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K C07D A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| A | US 4 981 864 A (VON DER SAAL ET AL) 1 January 1991 (1991-01-01) abstract column 7 - column 11 claim 1 | 1-12 |
| A | EP 0 189 103 A (BOEHRINGER MANNHEIM GMBH) 30 July 1986 (1986-07-30) abstract page 15, line 5 - line 6 | 1-12 |
| A | US 4 835 280 A (MARTENS ET AL) 30 May 1989 (1989-05-30) abstract column 11, line 61 - line 62 | 1-12 |
| | | -/- |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

6 December 2005

Date of mailing of the international search report

14/12/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Langer, O

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/010312

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| A | MAHADEVAN D ET AL: "Structure-based design of novel anti-cancer agents targeting aurora kinases" CURRENT MEDICINAL CHEMISTRY. ANTI-CANCER AGENTS, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 3, no. 1, January 2003 (2003-01), pages 25-34, XP009022702 ISSN: 1568-0118 abstract page 29, left-hand column, paragraph 3 – right-hand column, paragraph 1 figure 5 ----- | 1-12 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2005/010312

| Patent document cited in search report | | Publication date | | Patent family member(s) | | Publication date |
|--|---|------------------|--|---|--|--|
| US 4981864 | A | 01-01-1991 | | AU 2650688 A DE 3740985 A1 DK 666388 A EP 0318902 A2 HU 51486 A2 JP 1193219 A ZA 8808880 A | | 08-06-1989 15-06-1989 04-06-1989 07-06-1989 28-05-1990 03-08-1989 30-08-1989 |
| EP 0189103 | A | 30-07-1986 | | AU 580832 B2 AU 5224586 A DD 253620 A5 DE 3501497 A1 DK 20786 A ES 8801832 A1 ES 8900123 A1 FI 860228 A GR 860144 A1 HU 41791 A2 IL 77582 A JP 61167689 A SU 1470191 A3 US 4695567 A ZA 8600360 A | | 02-02-1989 24-07-1986 27-01-1988 24-07-1986 19-07-1986 01-05-1988 16-03-1989 19-07-1986 16-05-1986 28-05-1987 18-01-1990 29-07-1986 30-03-1989 22-09-1987 24-09-1986 |
| US 4835280 | A | 30-05-1989 | | NONE | | |